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ABSTRACT: Antibiotic resistance is posing a continuous threat to global public health and represents 
a huge burden for society as a whole. In the last decade, the interference with bacterial Quorum 
Sensing (QS) (i.e., cell-cell communication) mechanisms has extensively been investigated as a valid 
therapeutic approach in the pursuit of a next generation of antimicrobials. (S)-4,5-dihydroxy-2,3-
pentanedione, commonly known as (S)-DPD, a small signaling molecule that modulates QS in both 
Gram-negative and Gram-positive bacteria, is phosphorylated by LsrK and the resulting phospho-DPD 
activates QS. We designed and prepared a small library of DPD derivatives, characterized by five 
different scaffolds and evaluated their LsrK inhibition in the context of QS interference. SAR studies 
highlighted the pyrazole moiety as an essential structural element for LsrK inhibition. Particularly, four 
compounds were found to be micromolar LsrK inhibitors (IC50 ranging between 100 µM and 500 µM) 
encouraging further exploration of novel analogues as potential new antimicrobials. 
  
1. INTRODUCTION 
Quorum Sensing (QS) is a cell-cell communication strategy that allows bacteria to act as a population 
by coordinating their gene expression.1–5 QS regulates different pathogenic processes such as biofilm 
formation,6–8 susceptibility to antibiotics9 and virulence factor production. It is therefore not surprising 
that QS modulation has emerged in the last decade as a potential tool to fight antibiotic resistance.10–13 
QS is mediated by the exchange of small signaling molecules termed autoinducers (AIs). Oligopeptides 
and N-acyl homoserine lactones (AHLs) are the most common QS mediators in Gram-positive and 
Gram-negative bacteria, respectively, while Autoinducer-2 (AI-2) features in both classes. Targeting 
AI-2-mediated QS would therefore result in broad spectrum antimicrobial activity. The precursor of 
AI-2, (S)-DPD, is biosynthesized intracellularly in a three steps pathway. S-adenosylmethionine (SAM) 
is demethylated by a methyltransferase to generate the toxic intermediate S-adenosylhomocysteine 
(SAH). In LuxS-containing organisms, the enzyme Pfs removes adenine from SAH to form S-
ribosylhomocysteine (SRH). Lastly, LuxS breaks down SRH into adenine and (S)-DPD. LuxS synthase 
is found in more than 70 evolutionary different bacterial species indicating that AI-2 mediates both 
inter- and intraspecies communication.14 The neo-synthetized (S)-DPD is released extracellularly with 
an unclear mechanism which might involve the membrane protein YdgG (Figure 1)15,16. Outside the 
cell membrane, linear (S)-DPD spontaneously rearranges into the two cyclic isomers S-DHMF and R-
DHMF (Figure 1).17 The aqueous environment allows for their hydration at C3 to form the two cyclic 
tetrahydrated isomers S-THMF and R-THMF (Figure 1). X-ray crystallography revealed that S-THMF, 
in the form of the borate ester S-THMF-borate, binds to the periplasmic protein LuxP18 activating QS 
in V. harveyi. In enteric bacteria, when a threshold level of AI-2 in the extracellular medium is reached, 
R-THFM is imported via the Lsr (LuxS regulated) ACBFG transporter19 and its linear form (i.e., S-
THP) is phosphorylated by LsrK. The resulting S-THP-phosphate, commonly known as phospho-DPD 
(P-DPD, Figure 1), binds to the transcriptional repressor LsrR20 that dissociates from the promoter 
region of the lsr operon, initiating the operon transcription. As a result, the expression of the transporter 
on the cell surface is increased as well as the internalization of AI-2 and the QS response (Figure 1).21 
Ultimately, P-DPD is processed by LsrG and LsrF to close the AI-2 signaling cycle. LsrG catalyzes P-
DPD isomerization to 3,4,4-trihydroxy-2-pentanone-5-phosphate (P-TPO, Figure 1)22 while LsrF acts 
as a thiolase and transfers an acetyl group from the hydrated form of P-TPO to coenzyme A to form 
dihydroxyacetone phosphate (DHAP, Figure 1) and acetyl-CoA (Figure1).22 Considering the 
complexity of the mechanism and its regulation, there is a great interest of the pharmaceutical 
community in identifying new compounds able to modulate QS to control bacterial virulence and 
reduce its negative effects, including mortality.23–25 To lay the foundation for the rational 
design/discovery of QS modulators/inhibitors, several attempts to crystallize QS receptors have been 
performed. LuxP from V. harveyi has been co-crystallyzed with S-THMF-borate (PDB ID: 1JX618) 
while its isomer, R-THMF, has been solved in complex with the LsrB transporter (PDB ID: 1TJY19). 
Lastly, the linear hydrated form of (S)-DPD has been shown to bind to the transcriptional repressor 
LsrR (PDB ID: 4L4Z20). 
 Figure 1: Biosynthesis, transport and degradation of (S)-DPD in enteric bacteria 
To date, several structure-activity relationship (SAR) studies have been carried out around the DPD 
backbone and the effects of substitution at the C1 position have been reported.
26–33 However, the 
exploration of new compound classes that are structurally distinctive from native DPD is needed to 
discover new antibacterial agents. In this study, we report on the design, synthesis and SAR of novel 
DPD-related compounds (Figure 2) with different “core structures”, involving modifications at the 
DPD diketo moiety. In particular, we explored five small libraries of DPD-inspired heterocyclic 
derivatives (Het-DPD derivatives, Figure 2). Lastly, the in vitro inhibitory effect of the new compounds 
against LsrK has been evaluated. Results obtained suggested that Het-DPD derivatives act as LsrK 
inhibitors and their analogs may be considered as useful templates for the discovery of new effective 
DPD-based antimicrobial agents. To the best of our knowledge, these are the first heterocyclic-based 
LsrK inhibitors reported to-date. 
 Figure 2: DPD-inspired heterocyclic compounds 
2. RESULTS AND DISCUSSION 
2.1 Compounds design 
LsrK belongs to a family of carbohydrate kinases called “FGGY family” whose members transfer a 
phosphate group from ATP to several sugars ranging from trioses to heptoses.34 In enteric bacteria, 
phosphorylation of DPD by LsrK represents the prerequisite activating step for AI-2 signaling. 
Modulation/inhibition of LsrK could therefore potentially attenuate AI-2-related pathogenesis and LsrK 
could be a new and attractive anti-infective target to further explore.  
Previous studies evidenced that both the hydroxyl groups at C4 and C5 of DPD (Figure 2) are essential 
for phosphorylation. It has been demonstrated that DPD is phosphorylated at position five and that 
phosphorylation occurs only when the hydroxyl group at C4 is not derivatized.
35 Starting from these 
considerations, we herein designed new DPD-related compounds where the portions essential for LsrK-
mediated phosphorylation (i.e., the two hydroxyl groups at C4 and C5) are kept constant while the 
diketo moiety of DPD is embedded in heteroaromatic rings. The strategy of incorporating the carbonyl 
groups at C2 and C3 in heteroaromatic moiety may allow to obtain compounds stable in solution, and 
to avoid the open/closed equilibrium typical of the majority of the DPD-analogs reported so far. e 
focused our attention on different heterocyclic scaffolds decorated with different aliphatic and/or 
aromatic moieties (Schemes 1 – 4), with the final aim to investigate the chemical space of compounds 
structurally related to DPD. Among the wide variety of heterocycles, we selected annulated pyridines, 
pyridines, pyrimidines and pyrazoles, given their high frequency of occurrence in several natural or 
synthetic drugs used for their antibacterial36,37, antifungal38–41 anticancer42–45 and anti-inflammatory46–48 
properties, just to cite a few.  
2.2 Synthesis 
Target compounds (Schemes 1 – 4) can be easily prepared applying our recently developed protocol, 
starting from intermediate 1 bearing an ethyne group, suitable for further chemical diversification.49 
The synthesis of monosubstituted annulated pyridines-Het-DPD derivatives (Figure 2, series A) was 
accomplished via a one pot, microwave-assisted, palladium-catalyzed strategy, coupling alkyne 1 with 
o-bromoaldehydes. The resulting Sonogashira products were reacted with ammonium acetate as 
imination reagent and then deprotected (Scheme 1). Briefly, alkyne 1 was dissolved in DMF and then 
Pd(OAc)2, PPh3, KOAc and the appropriate o-bromoaldehyde were added. The reaction mixtures were 
irradiated at 80 °C for 1 – 2 hours, ammonium acetate was added and the resulting mixtures were 
irradiated again at 150 °C, thus affording the desired protected products 3a-g (Scheme 1). 
Heteroaromatic o-bromoaldehydes (i.e., 3-bromofuran-2-carbaldehyde 2e, 3-bromothiophene-2-
carbaldehyde 2f and 5-bromo-2-methyl-4-thiazolecarboxaldehyde 2g) led to isolation of the 
corresponding furopyridine, thienopyridine and thiazolopyridine derivatives 3e-f. Final acidic treatment 
yielded the monosubstituted annulated pyridines-Het-DPD derivatives 4a-g (Scheme 1).  
 Scheme 1: Synthesis of monosubstituted annulated pyridines-Het-DPD derivatives 4a-g. Reagents and 
conditions: (a) 2a-g (0.9 eq), Pd(OAc)2 (1.8% mol), PPh3 (3.6% mol), KOAc (1.8 eq), DMF, mw, 80 
°C, 1h – 2h; (a’) NH4OAc (1.8 eq), MW, 150 °C, 2h – 3h; (b) 12M HCl (cat.), 1,4-dioxane, 0 °C to rt, 
1h – 3h 
Sonogashira coupling43 of terminal alkyne 1 with acyl chlorides, followed by addition of amidinium 
salts to the corresponding ynones and final acidic removal of the acetal protecting group provided rapid 
access to 2,4,6-trisubstituted pyrimidines-Het-DPD derivatives (Figure 2, series B). Benzoyl chloride 
5a was selected to screen three different conditions for the synthesis of ynone 6a. Surprisingly, copper-, 
ligand- and solvent-free acylation51 as well as the use of a mixture of PdCl2(CH3CN)2, Sphos and 
Cs2CO3
26 did not furnish the desired product. Good results were obtained with the copper- and 
palladium-catalyzed system proposed by Karpov et al.50 which allowed us to obtain compound 6a with 
a yield of 87%.52 Three different ynones (6a-c) were reacted with six different amidinium salts and the 
resulting products 7a-f treated under acidic conditions (i.e., Scheme 2, conditions c) to afford the 2,4,6-
trisubstituted pyrimidines-Het-DPD derivatives 8a-f with moderate to excellent yields (i.e., 43% – 
82%). 
 Scheme 2: Synthesis of 2,4,6-trisubstituted pyrimidines-Het-DPD derivatives 8a-f. Reagents and 
conditions: (a) 5a-c (1.5 eq), PdCl2(PPh3)2 (9% mol), CuI (3% mol), Et3N (1.25 eq), THF, rt, overnight; 
(b) R2NHNH2*HCl (1.2 eq), Na2CO3*10 H2O (3.0 eq), 40 °C, overnight; (c) 12M HCl (cat.), 1,4-
dioxane, 0 °C to rt, 1h – 3h 
The 2,3,4,6-tetrasubstituted pyridines-Het-DPD derivatives (Figure 2, series C) were easily obtained 
following the one-pot, three-component and acid-free methodology developed by Bagley et al. This 
heteroannulation combines a Michael acceptor with a nucleophile in the presence of an excess (10.0 eq) 
of ammonium acetate (to generate, in situ, the enamine).53 Ethyl acetoacetate was selected as 
nucleophile to have an additional diversification point (i.e., the carboxylic ester moiety) and reaction 
with 6a (i.e., the Michael acceptor) in refluxing ethanol provided intermediate 9a with 92% yield 
(Scheme 3). Tetrasubstituted pyridines 9a and 9b (from ynone 6b), were hydrolyzed in basic conditions 
and then treated with hydrochloric acid to give target compounds 11a-b with excellent yields (i.e., 80% 
and 72%, respectively). 
 
 Scheme 3: Synthesis of 2,3,4,6-tetrasubstituted pyridines-Het-DPD derivatives 11a-b. Reagents and 
conditions: (a) Ethyl acetoacetate (10.0 eq), EtOH, 50 °C, overnight; (b) 1M NaOH (3.0 eq), EtOH, 0 
°C to rt, overnight; (c) 12M HCl (cat.), 1,4-dioxane, 0 °C to rt, 1h – 3h 
The synthesis of 3,5-disubstituted (series D) and 1,3,-5-trisubstituted pyrazoles-Het-DPD derivatives 
(series E) started with the production of three additional aliphatic (i.e., isopropyl, cyclopentyl and 
adamantane 6d-f) and one aromatic (i.e., furanyl 6g) ynones. Each of the seven ynones (6a-g) was 
reacted with two different hydrazines (i.e., hydrazine and methylhydrazine) to generate, respectively, 
3,5-disubstituted (12a-g) and 1,3,5-trisubstituted (13a-g) protected pyrazoles. Final acidic deprotection 
afforded the targeted products 14a-g and 15a-g with excellent yields (i.e., 67% – 92%, Scheme 4). 
 
Scheme 4: Synthesis of 3,5-disubstituted and 1,3,5-trisubstitted pyrazoles-Het-DPD derivatives 14a-g 
and 15a-g. Reagents and conditions: (a) R1COCl (1.5 eq), PdCl2(PPh3)2 (9% mol), CuI (3% mol), Et3N 
(1.25 eq), THF, rt, overnight; (b) R2NHNH2 (1.3 eq), EtOH, rt, overnight; (c) 12M HCl (cat.), 1,4-
dioxane, 0 °C to rt, 1h – 3h 
2.3 Screening of LsrK inhibitors 
All the prepared compounds were assayed for inhibitory activity against LsrK at 200 µM concentration. 
Unexpectedly, only four compounds (belonging to series D and series E) among the 29 prepared, 
resulted effective in inhibiting LrsK. Compounds 12a, 12b (series D) and 13a, 13b (series E) showing 
an inhibition percentage higher than 40%, were retested at different concentrations (Table 1) and their 
IC50 values calculated. In Figure 3 the dose-response curves together with the IC50 values of 
compounds 12a, 12b, 13a, 13b are reported. 
 
Figure 3: Dose-response curves against LsrK for compounds 12a, 12b, 13a, 13b. Data points represent 
the mean ±SD of two independent experiments (n = 4) 
To evaluate the specificity of compounds 12a, 12b, 13a, 13b, these were further tested against 
glycerokinase, which has high sequence similarity (i.e., 41.2%) to LsrK. None of the compounds 
showed activity against glycerokinase (Figure S1, SI). To sum up, pyrazole-containing DPD 
derivatives emerged as the most interesting LsrK inhibitors among the series under investigation. 
Series Structure Compound R
1
 R
2
 X Y N 
Inhibition 
(%) 
SD 
Annulated 
pyridines and 
derivatives 
Series A 
 
3a H 
― 
H H H 14.91 1.53 
3b p-CH3 H H 2 1.66 1.22 
3c m-OH H H 2 28.55 3.83 
3d o-F H H 2 1.76 0.94 
3e H O H 1 5.75 1.41 
3f H S H 1 11.06 4.02 
3g CH3 S N 1 6.32 2.35 
Annulated 
pyridines and 
derivatives 
Series A 
 
4a H 
― 
H H 2 0.48 0.63 
4b p-CH3 H H 2 0.40 0.39 
4c m-OH H H 2 1.67 1.55 
4d o-F H H 2 0.65 0.41 
4e H O H 1 2.07 1.00 
4f H S H 1 0.17 0.42 
4g CH3 S N 1 0.10 0.42 
2,4,6-
trisubstituted 
pyrimidines 
Series B 
 
7a Ph CH3 
― ― ― 
9.41 1.41 
7b Ph Cyp 15.18 4.39 
7c Cyp Ph 0.76 0.74 
7d Cyp p-Pyr 21.22 3.23 
7e 2-thiophene n-propyl 0.96 0.85 
7f 2-thiophene m-F-Ph 0.20 0.33 
2,4,6-
trisubstituted 
pyrimidines 
Series B 
 
8a Ph CH3 
― ― ― 
0.22 0.69 
8b Ph Cyp 24.48 3.32 
8c Cyp Ph 21.65 2.37 
8d Cyp p-Pyr 2.94 1.11 
8e 2-thiophene n-propyl 47.76 2.94 
8f 2-thiophene m-F-Ph 19.79 1.42 
  
Series Structure Compound R
1
 R
2
 X Y N 
Inhibition 
(%) 
SD 
2,3,4,6-
tetrasubstituted 
pyridines 
Series C 
 
9a Ph CH3CH2 
― ― ― 
0.10 0.07 
9b Cyp CH3CH2 0.36 0.66 
10a Ph H 0 1.69 
10b Cyp H 6.26 0.65 
2,3,4,6-
tetrasubstituted 
pyridines 
Series C 
 
11a Ph 
― ― ― ― 
0.81 0.59 
11b Cyp 1.33 0.49 
3,5-
disubstituted 
pyrazoles 
Series D 
 
12a Ph 
― ― ― ― 
53.60 5.67 
12b 2-furanyl 43.48 26.98 
12c 2-thiophene 26.50 5.52 
12d i-Pr 7.14 1.78 
12e Cyp 1.47 0.26 
12f Cyclopentyl 0 0.21 
12g Adamantane 0 0.81 
  
Series Structure Compound R
1
 R
2
 X Y N 
Inhibition 
(%) 
SD 
1,3,5-
trisubstitted 
pyrazoles 
Series E 
 
13a Ph 
― ― ― ― 
78.05 3.44 
13b 2-furanyl 51.63 11.91 
13c 2-thiophene 0 0.22 
13d i-Pr 0 0.67 
13e Cyp 0 0.57 
13f Cyclopentyl 0 0.82 
13g Adamantane 0 0.11 
13h m-CH3-Ph 1.07 0.91 
13i m-CN-Ph 0 0.51 
13j m-Cl-,m-F-Ph 4.42 2.14 
13k p-N(CH3)2-Ph 0.19 1.11 
13l 3-isoxazole 9.83 1.74 
13m 2-indole 4.38 2.39 
13n m-Pyr 4.92 5.13 
13o CyHex 1.51 1.50 
3,5-
disubstituted 
pyrazoles 
Series D 
 
14a Ph 
― ― ― ― 
0 0.02 
14b 2-furanyl  0 0.05 
14c 2-thiophene 0 1.16 
14d i-Pr 0 0.06 
14e Cyp 0 0.08 
14f Cyclopentyl 0 0.96 
14g Adamantane 0 0.44 
1,3,5-
trisubstitted 
pyrazoles 
Series E 
 
15a Ph 
― ― ― ― 
0 0.46 
15b 2-furanyl  0 0.66 
15c 2-thiophene 0 0.05 
15d i-Pr 0 0.24 
15e Cyp 0 0.47 
15f Cyclopentyl 0 0.32 
15g Adamantane 0 0.72 
  
Series Structure Compound R
1
 R
2
 X Y N 
Inhibition 
(%) 
SD 
3,5-
disubstituted 
pyrazoles 
New pyrazole 
derivatives 
 
16a CH3CH2 
― ― 
― 
― 
0 0.62 
16b i-Pr  0 0.96 
16c Cyp  0 0.70 
16d (CH2)2-CN  0 0.83 
16e Cyclopentyl  0 0.59 
16f Ph  0 0.53 
3,5-
disubstituted 
pyrazoles  
New pyrazole 
derivatives 
 
18 ― ― ― ― ― 2.01 0.78 
3,5-
disubstituted 
pyrazoles 
New pyrazole 
derivatives 
 
22a 
― ― 
H 
― 
0 5.56 2.34 
22b H 2 0 0.64 
22c O 1 31.13 1.83 
22d N-Ac 1 2.07 1.65 
 
Table 1: Activities of the synthesized DPD-IHs 
 
 
  
2. Structure-Activity Relationship (SAR) studies of pyrazole-containing DPD derivatives  
The results of the first LsrK screening highlighted the pyrazole moiety as the most promising scaffold. 
Accordingly, we further explored the 1,3,5-trisubstituted pyrazole series (series E), applying our 
synthetic protocol which permits an easy access to molecular diversity at three different diversification 
points, as outlined in Figure 4. Based on synthetic feasibility and commercial availability of the starting 
materials, nineteen new 1,3,5-trisubstituted pyrazole derivatives have been prepared by installing 
different aliphatic and aromatic substituents at position one (Scheme 5) and three (Scheme 6) as well as 
by replacing at position five the cyclohexylidene protecting group with aliphatic rings of different sizes 
(Scheme 7). Moreover, the dioxolane ring was removed (compound 18, Scheme 7).  
 
Figure 4: Further diversification of 1,3,5-trisubstituted pyrazolic compounds 
For modification at N1 the effects of aliphatic (linear, branched and cyclic) and aromatic substituents on 
bioactivity were investigated. The synthesis of this second set of 1,3,5-trisubstituted pyrazoles-Het-
DPD derivatives (16a-f) started from ynone 6a to which was added an excess (1.3 eq) of the 
corresponding hydrazine.  
 
Scheme 5: Synthesis of the first new set of 1,3,5-trisubstituted pyrazoles-Het-DPD derivatives 16a-f. 
Reagents and conditions: (a) R1NHNH2 (1.3 eq), EtOH, rt, overnight 
Several analogues where the phenyl at position three of the pyrazole nucleus was replaced with other 
aliphatic, aromatic and heteroaromatic rings were then studied. Compounds 16h-o (Scheme 6) were 
readily prepared by condensation of eight  new ynones synthetized by us with methylhydrazine. 
 Scheme 6: Synthesis of the second new set of 1,3,5-trisubstituted pyrazoles-Het-DPD derivatives 13h-
o. Reagents and conditions: (a) R1COCl (1.5 eq), PdCl2(PPh3)2 (9% mol), CuI (3% mol), Et3N (1.25 
eq), THF, rt, overnight; (b) MeNHNH2 (1.3 eq), EtOH, rt, overnight 
Lastly, to study the relevance of the dioxolane ring  on biological activity, we prepared compound 18, 
where it was completely removed. Additionally, derivatives 22a-d, bearing acetal substituents with 
different steric properties were also synthesized. Compound 18 was prepared reacting benzoyl chloride 
5a with 1-propyne 17 and the resulting ynone 6p with methylhydrazine as previously described 
(Scheme 7A). By reaction of the diol 19 with an excess (3.0 eq) of the corresponding ketone and a 
catalytic amount of p-TSA in neat conditions, further acylation with 5a and condensation with 
methylhydrazine the desired five new pyrazoles-Het-DPD 22a-d (Scheme 7B) were obtained. It has to 
be noted that 4-piperidone was found not to be suitable for our purpose as the free basic nitrogen 
impeded the Sonogashira coupling with benzoyl chloride while N-acetylpiperidone did not show any 
reactivity issue and compound 22d could be isolated with 44% yield. 
 Scheme 7: A) Synthesis of compound 18. Reagents and conditions: (a) 5a (1.5 eq), 1-propyne (1.0 eq), 
PdCl2(PPh3)2 (9% mol), CuI (3% mol), Et3N (1.25 eq), THF, rt, overnight; (b) MeNHNH2 (1.3 eq), 
EtOH, rt, overnight. B) Synthesis of the third new set of 1,3,5-trisubstituted pyrazoles-Het-DPD 
derivatives 22a-d. Reagents and conditions: (c) Ketone (3.0 eq), p-TSA (cat.), rt, overnight 
All the prepared 1,3,5-trisubstituted pyrazoles-Het-DPD were assayed for inhibitory activity against 
LsrK at 200 µM concentration, according to the protocol previously described.54 The obtained results 
confirmed that the presence of the dioxolane ring at position 5 of the pyrazole moiety is essential for 
the binding to LsrK and that acetals derivatives have a better profile respect to the corresponding diols. 
Overall, the results indicate that the most active LsrK inhibitor is compound 13a, bearing a methyl 
group at N1, a phenyl group at C3 and an acetal moiety at position five. 
2.5 Molecular modeling studies 
To support the SAR analysis and to inspect the molecular basis of their binding to LsrK, all the 
compounds were docked into the binding site of the LsrK crystal structure (PDB ID: 5YA1) using 
Glide, a molecular docking program reliable for predicting the binding mode of small molecules in 
protein complexes. Hence, docking poses were analyzed for both interactions and geometry. At first, 
we considered the modification at the diol moiety of DPD, our inspiring molecule, since in vitro 
experiments suggested the presence of the dioxolane ring in the Het-DPD derivatives as essential for 
the binding to LsrK.  We observed that the non-polar cyclohexane ring of acetal compounds can form 
electrostatic interactions with the surrounding environment. Compounds bearing the diol moiety 
showed an opposite orientation in the binding site (Figure S4, SI). The orientation of the diol groups 
towards the negative electrostatic potential surface of the binding site (Glu 454 and Thr 456) resulted in 
repulsion effects, thus explaining the weaker binding of diols compared with acetals.  
We then focused on pyrazole Het-DPD derivatives (series D and series E) since the in vitro results of 
the first LsrK screening highlighted the pyrazole moiety as the most promising scaffold. In line with 
experimental data, compound 13a gave the best interactions. Although compounds 12a and 13a, which 
differ only in the presence of N1-CH3, showed similar binding poses, we observed that the most active 
inhibitor 13a formed a hydrogen bond interaction with Thr 275, whereas 12a with Phe 276 and Gln 278 
(Figure S2, SI). Hence, we speculated that the interaction with Thr 275 may be involved in the 
substrate phosphorylation reaction. The binding poses of 12a and 13a (Figure S3, SI and Figure 5) are 
similar to those of the less active furanyl-substituted derivatives 12b and 13b,  with the only exception 
of the “pyrazole ring flipping”, caused by the bulky N1-CH3 group. The conformation of the pyrazole in 
12a and 13a resulted in a better methyl stabilization energy of N1-CH3, thus favoring the interaction 
with the target. Moreover, the oxygen of the furan ring of 13b (Figure 5) originated a negative 
electrostatic potential and the local binding site environment, for example the Thr 456 residue 
contributed to the electrostatic repulsion.  
Starting from these observations, further Het-DPD derivatives potentially able to better interact with 
LsrK will be designed and synthetized in the next future. 
 
 Figure 5. Compound 13a (left) and 13b (right) binding pose in the LsrK binding site (PDB ID: 5YA1). 
Hydrogen bond interactions (red dashed line) are shown along with active site residues. Electrostatic 
potential surfaces were presented as mesh (blue-positive potential and red-negative potential) 
3. CONCLUSIONS 
Resistance to antibiotics is constantly increasing and it is estimated that, by 2050, multidrug resistant 
bacteria will kill more people than cancer.55 In the last decade, modulation of QS has become an 
attractive therapeutic strategy to fight bacterial resistance. Two different DPD-related compounds (i.e., 
isobutyl-DPD and phenyl-DPD) have already shown their activity in combination with gentamicin and 
small molecules able to modulate/inhibit QS are therefore considered interesting “non-conventional” 
tools to be used in combination with classical antibiotics.10–13 
As a continuation of our recent findings, where, applying a virtual screening approach we were able to 
identify 2-substituted amino benzoic acids as LsrK inhibitors, in this communication, we report for the 
first time on the “ad hoc” design and synthesis of potential LrsK inhibitors structurally related to DPD. 
The medicinal chemistry efforts presented in this work provided 48 Het-DPD derivatives, characterized 
by different heterocyclic scaffolds and led to the identification of effective representatives 
characterized by in vitro LsrK enzymatic activity (IC50) in the micromolar range. All the target 
compounds have been easily prepared in maximum four synthetic steps, thus allowing to easily explore 
the chemical space of DPD. Remarkably, four compounds displayed IC50 values between 100 µM and 
500 µM, evidencing the 3,5-disubstituted and 1,3,5-trisubstituted pyrazole structures as the best 
scaffolds. Moreover, an in-depth SAR campaign was performed, synthetizing other nineteen 1,3,5-
trisubstituted pyrazole analogues. The systematic ligand-based approach and SAR studies, led to the 
identification of compound 13a, with an IC50 value of 119 µM as a promising Hit for future chemical 
development of novel LsrK inhibitors. Future work in our laboratory will focus on a hit-to-lead process 
to increase LsrK inhibition by further diversification and functionalization of the heterocyclic core and 
the evaluation of these novel derivatives for their potential as QS-interfering compounds in the 
treatment of bacterial infections. 
 
   
4. EXPERIMENTAL SECTION 
4.1 Chemistry 
Chemicals and solvents were obtained from commercial suppliers and were used without further 
purification. All dry reactions were performed under nitrogen atmosphere using commercial dry 
solvents. Flash column chromatography was performed on a silica column using 230400 mesh silica 
gel or Grace Reveleris X2 flash chromatography system using silica gel packed Macherey Nagel 
Chromabond Flash BT cartridges (60 Å, 45 μm) and Grace Reveleris flash Cartridges (60 Å, 40 μm). 
Thin layer chromatography was performed on Macherey Nagel precoated TLC aluminum sheets with 
silica gel 60 UV254 (5 μm – 17 μm). TLC visualization was accomplished by irradiation with a UV 
lamp (254 nm) and/or staining with KMnO4 solutions. 
1H NMR spectra were recorded at room 
temperature on a Bruker Avance spectrometer operating at 300 MHz. Chemical shifts are given in ppm 
(δ) from tetramethylsilane as an internal standard or residual solvent peak. Significant 1H NMR data 
are tabulated in the following order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet; dd, doublet of doublets; dt, doublet of triplets; td, triplet of doublets; br, broad), coupling 
constant(s) in hertz, number of protons. Proton decoupled 13C NMR data were acquired at 100 MHz. 
13C chemical shifts are reported in parts per million (δ, ppm). All NMR data were collected at room 
temperature (25 °C). Analytical, preparative HPLC and Electron Spray Ionization (ESI) mass spectra 
were performed on an Agilent UHPLC (1290 Infinity) and an Agilent Prep-HPLC (1260 Infinity) both 
equipped with a Diode Array Detector and a Quadrupole MS using mixture gradients of formic 
acid/water/acetonitrile as solvents. High-resolution electrospray ionization mass spectra (ESI-FTMS) 
were recorded on a Thermo LTQ Orbitrap (high-resolution mass spectrometer from Thermo Electron) 
coupled to an ‘Accela’ HPLC system supplied with a ‘Hypersil GOLD’ column (Termo Electron). All 
the intermediates and final compounds displayed ≥ 95.0% purity as determined by UHPLC (Agilent, 
1290 Infinity). For each compound, the retention rime (Rt) is expressed in minutes (min.). 
4.2 General procedures for the synthesis of monosubstituted annulated pyridines and 
derivatives (Series A) 
Synthesis of 3a-g: 1 (1.0eq ), Pd(OAc)2 (1.8 %mol), PPh3 (3.6 % mol), KOAc (1.8 eq) and the 
corresponding 2-bromoaryl(heteroaryl)aldehyde (0.9 eq) in dry DMF were mixed in a 5 mL microwave 
vial under N2 atmosphere. The mixture was stirred at 80 °C under microwave irradiation until starting 
material disappearance (usually 1 – 2 hours). After cooling to room temperature, NH4OAc (2.0 eq) was 
added and the mixture was stirred at 150 °C under microwave irradiation until disappearance of the 
corresponding Sonogashira product (usually 2 – 3 hours). The mixture was diluted with EtOAc and 
washed five times with water. The organic layer was dried over MgSO4, filtered and concentrated in 
vacuo. The crude was redissolved in ACN (1 mL), filtered and purified by preparative HPLC.56 
3-{1,4-dioxaspiro[4.5]decan-2-yl}isoquinoline (3a): brown oil, 55%, Rf  = 0.15 (CyH/EtOAc 9:1), 
UHPLC-ESI-MS: Rt = 2.96 min., m/z = 270.2 [M + H]
 +. 1H NMR (300 MHz, CDCl3) δ 9.18 (s, 1H), 
7.95 (d, J = 8.1 Hz, 1H), 7.87 – 7.82 (m, 2H), 7.68 (t, J = 7.5 Hz, 1H), 7.57 (t, J = 7.5 Hz, 1H), 5.39 (t, 
J = 6.7 Hz, 1H), 4.55 (t, J = 7.5 Hz, 1H), 4.01 (t, J = 7.5 Hz, 1H), 1.86 – 1.63 (m, 8H), 1.49 – 1.46 (m, 
2H) ppm; 13C NMR (100 MHz, CDCl3) δ 153.7, 152.1, 136.3, 130.5, 127.9, 127.5, 127.0, 126.7, 116.1, 
110.8, 77.8, 70.1, 36.1, 35.2, 25.2, 24.0, 23.9 ppm. 
3-{1,4-dioxaspiro[4.5]decan-2-yl}-7-methylisoquinoline (3b): orange oil, 43%, Rf  = 0.45 
(CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 2.94 min., m/z = 284.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 9.11 (s, 1H), 7.85 (d, J = 4.8 Hz, 1H), 7.79 (s, 1H), 7.61 (s, 1H), 7.41 (dd, J = 1.5 Hz, J = 8.4 
Hz, 1H), 5.37 (t, J = 7.0 Hz, 1H), 4.54 (dd, J = 6.8 Hz, J = 8.2 Hz, 1H), 4.00 (dd, J = 6.8 Hz, J = 8.2 
Hz, 1H), 2.54 (s, 3H), 1.86 – 1.77 (m, 4H), 1.74 – 1.63 (m, 4H), 1.49 – 1.47 (m, 2H) ppm; 13C NMR 
(100 MHz, CDCl3) δ 153.7, 151.6, 140.9, 136.6, 129.3, 127.3, 126.4, 125.7, 115.6, 110.8, 77.8, 70.2, 
36.1, 35.3, 25.2, 24.1, 23.9, 22.1 ppm. 
3-{1,4-dioxaspiro[4.5]decan-2-yl}isoquinolin-7-ol (3c): brown oil, 45%, Rf  = 0.25 (CyH/EtOAc 3:1), 
UHPLC-ESI-MS: Rt = 2.29 min., m/z = 286.2 [M + H]
 +. 1H NMR (300 MHz, MeOD) δ 8.99 (s, 1H), 
8.21 (s, 1H), 7.85 (s, 1H), 7.38 (dd, J = 2.4 Hz, J = 8.9 Hz, 1H), 7.30 (d, J = 2.4 Hz, 1H), 5.29 (t, J = 
6.7 Hz, 1H), 4.47 (dd, J = 6.6 Hz, J = 8.1 Hz, 1H), 3.92 (dd, J = 7.1 Hz, J = 8.1 Hz, 1H), 1.87 – 1.67 
(m, 8H), 1.52 – 1.48 (m, 2H), ppm; 13C NMR (100 MHz, MeOD) δ 158.2, 151.2, 149.7, 131.2, 129.6, 
125.2, 122.1, 118.1, 112.0, 109.2, 78.9, 71.2, 37.3, 36.3, 26.4, 25.2, 25.0 ppm. 
3-{1,4-dioxaspiro[4.5]decan-2-yl}-5-fluoroisoquinoline (3d): brown oil, 73%, Rf  = 0.22 
(CyH/EtOAc 9:1), UHPLC-ESI-MS: Rt = 3.27 min., m/z = 288.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 9.18 (s, 1H), 8.08 (s, 1H), 7.72 (d, J = 8.2 Hz, 1H), 7.48 (dt, J = 5.1 Hz, J = 7.9 Hz, 1H), 7.36 
– 7.30 (m, 1H), 5.37 (t, J = 6.6 Hz, 1H), 4.53 (dd, J = 6.8 Hz, J = 8.2 Hz, 1H), 4.01 (dd, J = 6.6 Hz, J = 
8.2 Hz, 1H), 1.85 – 1.73 (m, 4H), 1.68 – 1.61 (m, 4H), 1.48 – 1.45 (m, 2H) ppm; 13C NMR (100 MHz, 
CDCl3) δ 157.6 (d, J = 254.1 Hz), 154.4, 151.5 (d, J = 3.0 Hz), 128.8 (d, J = 4.9 Hz), 126.9 (d, J = 7.5 
Hz), 126.6, 123.2 (d, J = 4.4 Hz), 114.0 (d, J = 19.1 Hz), 111.0, 109.1 (d, J = 3.7 Hz), 77.0, 70.0, 36.1, 
35.2, 25.1, 24.0 (d, J = 8.3 Hz) ppm. 
5-{1,4-dioxaspiro[4.5]decan-2-yl}furo[2,3-c]pyridine (3e): brown oil, 53%, Rf  = 0.22 (CyH/EtOAc 
9:1), UHPLC-ESI-MS: Rt = 2.54 min., m/z = 260.2 [M + H]
 +. 1H NMR (300 MHz, CDCl3) δ 8.79 (s, 
1H), 7.81 (s, 1H), 7.76 (d, J = 2.0 Hz, 1H), 6.82 (d, J = 1.2 Hz, 1H), 5.32 (t, J = 6.7 Hz, 1H), 4.49 (t, J 
= 8.1 Hz, 1H), 3.95 (t, J = 7.5 Hz, 1H), 1.81 – 1.75 (m, 5H), 1.71 – 1.64 (m, 3H), 1.50 – 1.46 (m, 2H) 
ppm; 13C NMR (100 MHz, CDCl3) δ 153.2, 151.5, 148.5, 134.8, 132.8, 112.4, 110.8, 106.3, 77.9, 70.4, 
36.2, 35.2, 25.2, 24.1, 23.9 ppm. 
5-{1,4-dioxaspiro[4.5]decan-2-yl}thieno[2,3-c]pyridine (3f): brown oil, 66%, Rf  = 0.24 (CyH/EtOAc 
9:1), UHPLC-ESI-MS: Rt = 2.67 min., m/z = 276.2 [M + H]
 +. 1H NMR (300 MHz, CDCl3) δ 9.05 (s, 
1H), 7.95 (s, 1H), 7.72 (d, J = 5.3 Hz, 1H), 7.37 (d, J = 5.3 Hz, 1H), 5.35 (t, J = 6.7 Hz, 1H), 4.52 (t, J 
= 7.5 Hz, 1H), 3.96 (t, J = 7.5 Hz, 1H), 1.81 – 1.75 (m, 4H), 1.71 – 1.64 (m, 4H), 1.49 – 1.45 (m, 2H) 
ppm; 13C NMR (100 MHz, CDCl3) δ 154.1, 145.6, 143.8, 135.2, 132.5, 123.2, 114.0, 110.8, 77.7, 70.3, 
36.1, 35.2, 25.2, 24.0 (d, J = 12.1 Hz) ppm. 
6-{1,4-dioxaspiro[4.5]decan-2-yl}-2-methyl-[1,3]thiazolo[5,4-c]pyridine (3g): brown oil, 59%, Rf  = 
0.23 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 2.80 min., m/z = 291.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 9.13 (s, 1H), 8.03 (s, 1H), 5.33 (t, J = 6.6 Hz, 1H), 4.52 (t, J = 7.5 Hz, 1H), 3.97 (t, J = 7.5 
Hz, 1H), 2.87 (s, 3H), 1.82 – 1.62 (m, 8H), 1.50 – 1.46 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 
168.2, 154.9, 149.2, 144.8, 143.3, 112.5, 111.0, 77.7, 70.2, 36.2, 35.1, 25.2, 24.1, 23.9, 20.2 ppm. 
Synthesis of 4a-g: a stirred solution of the protected annulated pyridine 3a-g in 1,4-dioxane was cooled 
to 0 °C using an ice bath. A catalytic amount of concentrated HCl was added. The reaction was stirred 
at room temperature for 1 – 3 hours. Solvent was evaporated under reduced pressure, the crude was 
redissolved in ACN (1 mL), filtered and purified by preparative HPLC. 
1-(isoquinolin-3-yl)ethane-1,2-diol (4a): white solid, 90%, Rf  = 0.41 (CHCl3/MeOH 9:1), UHPLC-
ESI-MS: Rt = 1.12 min., m/z = 190.2 [M + H]
 +. 1H NMR (300 MHz, MeOD) δ 9.20 (s, 1H), 8.08 (d, J 
= 8.2 Hz, 1H), 7.94 (d, J = 7.6 Hz, 2H), 7.78 (t, J = 7.3 Hz, 1H), 7.66 (t, J = 7.4 Hz, 1H), 4.95 – 4.92 
(m, 1H), 3.98 – 3.88 (m, 1H), 3.79 – 3.70 (m, 1H) ppm; 13C NMR (100 MHz, MeOD) δ 155.5, 152.7, 
135.1, 132.3, 128.9, 128.6, 127.8, 124.4, 118.9, 76.2, 67.7 ppm 
1-(6-methylisoquinolin-3-yl)ethane-1,2-diol (4b): yellowish solid, 54%, Rf  = 0.23 (DCM/MeOH 
19:1), UHPLC-ESI-MS: Rt = 1.31 min., m/z = 204.2 [M + H]
 +. 1H NMR (300 MHz, MeOD) δ 9.11 (s, 
1H), 7.97 (d, J = 8.4 Hz, 1H), 7.86 (s, 1H), 7.71 (s, 1H), 7.51 (dd, J = 1.4 Hz, J = 8.4 Hz, 1H), 4.95 – 
4.91 (m, 1H), 3.93 (dd, J = 4.0 Hz, J = 11.3 Hz, 1H), 3.74 (dd, J = 6.8 Hz, J = 11.3 Hz, 1H), 2.56 (s, 
3H) ppm; 13C NMR (100 MHz, MeOD) δ 155.4, 152.2, 143.3, 138.4, 130.9, 128.7, 127.9, 126.7, 118.5, 
76.1, 67.7, 22.1 ppm. 
1-(7-hydroxyisoquinolin-3-yl)ethane-1,2-diol (4c): yellow oil, 67%, Rf  = 0.50 (CHCl3/MeOH 9:1), 
UHPLC-ESI-MS: Rt = 0.41 min., m/z = 206.0 [M + H]
 +. 1H NMR (300 MHz, MeOD) δ 9.14 (s, 1H), 
7.97 (dd, J = 9.4 Hz, J = 16.6 Hz, 2H), 7.51 (dd, J = 1.5 Hz, J = 8.7 Hz, 1H), 7.41 (s, 1H), 4.98 – 4.95 
(m, 1H), 3.89 (dd, J = 4.5 Hz, J = 11.3 Hz, 1H), 3.79 (dd, J = 6.2 Hz, J = 11.2 Hz, 1H) ppm; 13C NMR 
(100 MHz, MeOD) δ 164.9, 159.2, 148.5, 133.8, 130.8, 129.9, 127.5, 120.7, 109.8, 74.4, 67.4 ppm. 
1-(5-fluoroisoquinolin-3-yl)ethane-1,2-diol (4d): white solid, 42%, Rf  = 0.47 (CHCl3/MeOH 9:1), 
UHPLC-ESI-MS: Rt = 1.44 min., m/z = 208.2 [M + H]
 +. 1H NMR (300 MHz, MeOD) δ 9.25 (s, 1H), 
8.11 (s, 1H), 7.91 (d, J = 7.8 Hz, 1H), 7.65 – 7.58 (m, 1H), 7.52 – 7.46 (m, 1H), 4.97 – 4.94 (m, 1H), 
3.97 (dd, J = 3.9 Hz, J = 11.3 Hz, 1H), 3.77 (dd, J = 6.4 Hz, J = 11.3 Hz, 1H) ppm; 13C NMR (100 
MHz, MeOD) δ 158.6 (d, J = 252.4 Hz), 156.3 (d, J = 1.5 Hz), 152.3 (d, J = 2.9 Hz), 130.1 (d, J = 4.6 
Hz), 128.4 (d, J = 7.7 Hz), 127.8 (d, J = 17.9 Hz), 124.6 (d, J = 4.4 Hz), 115.3 (d, J = 19.3 Hz), 111.0 
(d, J = 3.9 Hz),75.9, 67.3 ppm. 
1-{furo[3,2-c]pyridin-6-yl}ethane-1,2-diol (4e): yellow oil, 48%, Rf  = 0.33 (CHCl3/MeOH 9:1), 
UHPLC-ESI-MS: Rt = 0.48 min., m/z = 180.1 [M + H]
 +. 1H NMR (300 MHz, MeOD) δ 8.84 (s, 1H), 
8.12 (s, 1H), 7.93 (s, 1H), 7.05 (s, 1H), 4.96 – 4.91 (m, 1H), 3.86 (dd, J = 4.2 Hz, J = 11.2 Hz, 1H), 
3.73 (dd, J = 6.6 Hz, J = 11.2 Hz, 1H) ppm; 13C NMR (100 MHz, MeOD) δ 154.7, 152.5, 143.5, 139.9, 
132.1, 115.4, 107.7, 75.4, 67.8 ppm. 
1-{thieno[3,2-c]pyridin-6-yl}ethane-1,2-diol (4f): white solid, 73%, Rf  = 0.35 (CHCl3/MeOH 9:1), 
UHPLC-ESI-MS: Rt = 0.64 min., m/z = 196.0 [M + H]
 +. 1H NMR (300 MHz, MeOD) δ 8.97 (s, 1H), 
7.91 – 7.87 (m, 2H), 7.39 (d, J = 5.3 Hz, 1H), 4.82 (s, 1H), 3.80 (dd, J = 3.9 Hz, J = 11.2 Hz, 1H), 3.63 
(dd, J = 6.8 Hz, J = 11.2 Hz, 1H) ppm; 13C NMR (100 MHz, MeOD) δ 156.1, 147.7, 144.5, 136.8, 
134.9, 124.3, 116.5, 76.1, 67.9 ppm. 
1-{2-methyl-[1,3]thiazolo[4,5-c]pyridin-6-yl}ethane-1,2-diol (4g): yellow oil, 70%, Rf  = 0.39 
(CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 1.12 min., m/z = 211.2 [M + H]
 +. 1H NMR (300 MHz, 
MeOD) δ 9.03 (s, 1H), 8.16 (s, 1H), 4.91 (s, 1H), 3.90 (dd, J = 3.9 Hz, J = 11.3 Hz, 1H), 3.73 (dd, J = 
6.4 Hz, J = 11.1 Hz, 1H), 3.70 (s, 3H) ppm; 13C NMR (100 MHz, MeOD) δ 171.6, 157.2, 150.4, 146.7, 
143.2, 115.4, 76.0, 67.7, 19.9 ppm. 
4.3 General procedures for the synthesis of 2,4,6-trisubstituted pyrimidines (Series B) 
Synthesis of 6a-p: to a stirred solution of 1 (1.0 eq) in dry THF were added PdCl2(PPh3)2 (9%mol), 
CuI (3% mol) and the corresponding acyl chloride (1.5 eq). The reaction was stirred at room 
temperature for 2 minutes under N2 atmosphere. Et3N (1.25 eq) was added and the mixture was stirred 
at room temperature overnight. Solvent was removed under reduced pressure, the crude redissolved in 
EtOAc and washed three times with water. The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo to yield the corresponding ynone. The products were used without being 
purified. 
Synthesis of 7a-f: to a stirred solution of the corresponding ynone (1.0 eq) in THF was added Na2CO3 
(2.4 eq) and the corresponding amidine hydrochloride (1.2 eq). The mixture was stirred at reflux 
overnight. Solvent was evaporated under reduced pressure, the crude was redissolved in EtOAc and 
washed three times with water. The organic layer was dried over MgSO4, filtered and concentrated in 
vacuo. The crude was redissolved in ACN (1 mL), filtered and purified by preparative HPLC.57 
4-{1,4-dioxaspiro[4.5]decan-2-yl}-2-methyl-6-phenylpyrimidine (7a): orange oil, 42%, Rf  = 0.44 
(CyH/EtOAc 9:1), UHPLC-ESI-MS: Rt = 3.48 min., m/z = 311.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 8.09 – 8.07 (m, 2H), 7.78 (s, 1H), 7.51 – 7.50 (m, 3H), 5.15 (t, J = 6.6 Hz, 1H), 4.52 (t, J = 
7.8 Hz, 1H), 4.01 (dd, J = 6.2 Hz, J = 8.3 Hz, 1H), 2.76 (s, 3H), 1.76 – 1.66 (m, 8H), 1.48 – 1.46 (m, 
2H) ppm; 13C NMR (100 MHz, CDCl3) δ 170.1, 167.7, 164.8, 137.2, 130.8, 128.9, 127.3, 111.4, 109.7, 
77.3, 69.5, 36.0, 35.0, 26.1, 25.1, 24.0, 23.9 ppm. 
2-cyclopropyl-4-{1,4-dioxaspiro[4.5]decan-2-yl}-6-phenylpyrimidine (7b): orange oil, 51%, Rf = 
0.51 (CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 3.85 min., m/z = 337.2 [M + H]
 +. 1H NMR (300 
MHz, CDCl3) δ 8.09 – 8.07 (m, 2H), 7.71 (s, 1H), 7.50 – 7.48 (m, 3H), 5.13 (t, J = 6.6 Hz, 1H), 4.49 (t, 
J = 7.8 Hz, 1H), 4.01 (dd, J = 6.7 Hz, J = 7.8 Hz, 1H), 2.29 – 2.26 (m, 1H), 1.80 – 1.63 (m, 8H), 1.47 
(s, 2H), 1.21 (d, J = 4.7 Hz, 2H), 1.09 – 1.05 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 171.5, 
169.6, 164.3, 137.3, 130.7, 128.8, 127.2, 111.3, 109.3, 77.2, 69.5, 36.0, 35.0, 25.1, 24.0, 23.9, 18.0, 
10.8 (d, J = 5.2 Hz) ppm. 
4-cyclopropyl-6-{1,4-dioxaspiro[4.5]decan-2-yl}-2-phenylpyrimidine (7c): brown oil, 54%, Rf  = 
0.48 (CyH/EtOAc 9:1), UHPLC-ESI-MS: Rt = 3.94 min., m/z = 337.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 8.44 – 8.41 (m, 2H), 7.47 – 7.44 (m, 3H), 7.31 (s, 1H), 5.17 (t, J = 6.9 Hz, 1H), 4.53 (dd, J = 
7.1 Hz, J = 8.4 Hz, 1H), 4.07 (dd, J = 6.3 Hz, J = 8.4 Hz, 1H), 2.09 – 2.02 (m, 1H), 1.82 – 1.64 (m, 
8H), 1.51– 1.46 (m, 2H), 1.32 – 1.27 (m, 2H), 1.13 – 1.07 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) 
δ 172.4, 168.2, 163.4, 137.8, 130.3, 128.3, 128.1, 112.5, 111.2, 77.0, 69.5, 36.0, 35.1, 25.1, 24.0, 23.8, 
17.2, 11.1 (d, J = 7.3 Hz) ppm. 
4-cyclopropyl-6-{1,4-dioxaspiro[4.5]decan-2-yl}-2-(pyridin-2-yl)pyrimidine (7d): brown oil, 62%, 
Rf  = 0.52 (CHCl3/MeOH 5:1), UHPLC-ESI-MS: Rt = 2.62 min., m/z = 338.2 [M + H]
 +. 1H NMR (300 
MHz, CDCl3) δ 8.82 (ddd, J = 0.9 Hz, J = 1.8 Hz, J = 4.8 Hz, 1H), 8.44 (td, J = 1.0 Hz, J = 8.0 Hz, 
1H), 7.82 (dt, J = 1.8 Hz, J = 7.8 Hz, 1H), 7.38 – 7.36 (m, 2H), 5.29 (t, J = 6.6 Hz, 1H), 4.55 (dd, J = 
7.1 Hz, J = 8.5 Hz, 1H), 3.99 (dd, J = 6.0 Hz, J = 8.5 Hz, 1H), 2.18 – 2.12 (m, 1H), 1.79 – 1.62 (m, 
8H), 1.47– 1.44 (m, 2H), 1.26 – 1.22 (m, 2H), 1.18 – 1.11 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) 
δ 173.1, 169.4, 162.6, 155.1, 149.9, 136.8, 124.6, 123.9, 113.0, 111.3, 77.1, 69.8, 36.0, 34.8, 25.1, 24.0, 
23.8, 17.5, 11.4 (d, J = 2.8 Hz) ppm. 
4-{1,4-dioxaspiro[4.5]decan-2-yl}-2-(3-fluorophenyl)-6-(thiophen-2-yl)pyrimidine (7e): orange oil, 
57%, Rf  = 0.66 (CyH/EtOAc 9:1), UHPLC-ESI-MS: Rt = 4.03 min., m/z = 397.2 [M + H]
 +. 1H NMR 
(300 MHz, CDCl3) δ 8.33 – 8.30 (m, 1H), 8.24 – 8.19 (m, 1H), 7.85 (dd, J = 1.1 Hz, J = 3.7 Hz, 1H), 
7.72 (s, 1H) 7.54 (dd, J = 1.0 Hz, J = 5.0 Hz, 1H), 7.49 – 7.42 (m, 1H), 7.21 – 7.15 (m, 2H), 5.21 (t, J = 
6.6 Hz, 1H), 4.56 (dd, J = 7.1 Hz, J = 8.5 Hz, 1H), 4.13 (dd, J = 6.0 Hz, J = 8.5 Hz, 1H), 1.81 – 1.67 
(m, 8H), 1.51 – 1.49 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 170.3, 164.7, 162.7 (d, J = 3.2 Hz), 
161.5, 159.6, 142.8, 139.7 (d, J = 7.8 Hz), 130.2, 129.9 (d, J = 8.0 Hz), 128.3, 127.6, 123.9 (d, J = 2.7 
Hz), 117.6 (d, J = 21.4 Hz), 115.1 (d, J = 23.2 Hz), 111.4, 109.0, 77.2, 69.4, 36.0, 35.1, 25.1, 24.0, 23.9 
ppm. 
4-{1,4-dioxaspiro[4.5]decan-2-yl}-2-propyl-6-(thiophen-2-yl)pyrimidine (7f): orange oil, 57%, Rf  = 
0.57 (CyH/EtOAc 9:1), UHPLC-ESI-MS: Rt = 3.77 min., m/z = 345.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 7.77 (dd, J = 1.0 Hz, J = 3.7 Hz, 1H), 7.61 (s, 1H), 7.48 (dd, J = 1.0 Hz, J = 5.0 Hz, 1H), 7.12 
(dd, J = 3.8 Hz, J = 5.0 Hz, 1H), 5.10 (t, J = 6.5 Hz, 1H), 4.48 (dd, J = 7.2 Hz, J = 8.4 Hz, 1H), 3.99 
(dd, J = 6.0 Hz, J = 8.4 Hz, 1H), 2.88 (t, J = 7.5 Hz, 2H), 1.89 – 1.80 (m, 2H), 1.74 – 1.62 (m, 8H), 
1.45 (s, 2H), 1.00 (t, J = 7.4 Hz, 3H) ppm; 13C NMR (100 MHz, CDCl3) δ 170.9, 169.7, 159.3, 143.0, 
129.7, 128.2, 127.2, 111.3, 107.8, 76.9, 69.4, 41.1, 35.9, 34.9, 25.1, 24.0, 23.8, 21.8, 13.8 ppm. 
Synthesis of 8a-f: a stirred solution of the protected pyrimidine 7a-f in 1,4-dioxane was cooled to 0 °C 
using an ice bath. A catalytic amount of concentrated HCl was added. The reaction was stirred at room 
temperature for 1 – 3 hours. Solvent was evaporated under reduced pressure, the crude was redissolved 
in ACN (1 mL), filtered and purified by preparative HPLC.  
1-(2-methyl-6-phenylpyrimidin-4-yl)ethane-1,2-diol (8a): yellowish solid, 54%, Rf  = 0.58 
(CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 1.92 min., m/z = 231.2 [M + H]
 +. 1H NMR (300 MHz, 
MeOD) δ 8.13 – 8.11 (m, 2H), 7.90 (s, 1H), 7.54 – 7.52 (m, 3H), 4.75 – 4.72 (m, 1H), 3.92 (dd, J = 3.8 
Hz, J = 11.3 Hz, 1H), 3.78 (dd, J = 5.8 Hz, J = 11.3 Hz, 1H), 2.73 (s, 3H) ppm; 13C NMR (100 MHz, 
MeOD) δ 172.7, 168.7, 166.2, 138.4, 132.1, 130.1, 128.5, 112.4, 75.7, 67.2, 25.8 ppm. 
1-(2-cyclopropyl-6-phenylpyrimidin-4-yl)ethane-1,2-diol (8b): brown oil, 53%, Rf  = 0.58 
(CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 2.38 min., m/z = 257.2 [M + H]
 +. 1H NMR (300 MHz, 
MeOD) δ 8.12 – 8.10 (m, 2H), 7.82 (s, 1H), 7.51 – 7.49 (m, 3H), 4.72 – 4.69 (m, 1H), 3.92 (dd, J = 3.8 
Hz, J = 11.3 Hz, 1H), 3.76 (dd, J = 6.0 Hz, J = 11.2 Hz, 1H), 2.31 – 2.24 (m, 1H), 1.19 – 1.18 (m, 2H), 
1.09 – 1.06 (m, 2H) ppm; 13C NMR (100 MHz, MeOD) δ 172.6, 172.1, 165.7, 138.5, 132.0, 130.0, 
128.3, 111.7, 75.7, 67.2, 18.7, 11.0 ppm. 
1-(6-cyclopropyl-2-phenylpyrimidin-4-yl)ethane-1,2-diol (8c): brown oil, 46%, Rf  = 0.62 
(CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 2.55 min., m/z = 257.2 [M + H]
 +. 1H NMR (300 MHz, 
MeOD) δ 8.30 – 8.26 (m, 1H), 7.58 – 7.51 (m, 1H), 7.49 – 7.45 (m, 1H), 7.36 – 7.34 (m, 2H), 7.28 (s, 
1H), 4.63 (dd, J = 3.9 Hz, J = 6.1 Hz, 1H), 3.87 (dd, J = 3.9 Hz, J = 11.3 Hz, 1H), 3.69 (dd, J = 6.2 Hz, 
J = 11.3 Hz, 1H), 2.07 – 2.00 (m, 1H), 1.15 – 1.11 (m, 2H), 1.04 – 1.00 (m, 2H) ppm; 13C NMR (100 
MHz, MeOD) δ 174.0, 170.7, 164.6, 139.3, 131.5, 130.1, 129.4, 114.8, 75.7, 67.3, 17.9, 11.6 (d, J = 7.0 
Hz) ppm. 
1-[6-cyclopropyl-2-(pyridin-2-yl)pyrimidin-4-yl]ethane-1,2-diol (8d): yellowish solid, 67%, Rf  = 
0.62 (CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 1.50 min., m/z = 258.2 [M + H]
 +. 1H NMR (300 
MHz, MeOD) δ 8.71 (d, J = 4.2 Hz, 1H), 8.50 (d, J = 7.9 Hz, 1H), 7.99 (t, J = 7.0 Hz, 1H), 7.55 – 7.51 
(m, 1H), 7.49 – 7.47 (m, 1H), 4.80 – 4.77 (m, 1H), 3.94 (dd, J = 4.2 Hz, J = 11.3 Hz, 1H), 3.83 (dd, J = 
5.8 Hz, J = 11.3 Hz, 1H), 2.23 – 2.17 (m, 1H), 1.27 (d, J = 4.1 Hz, 2H), 1.18 – 1.14 (m, 2H) ppm; 13C 
NMR (100 MHz, MeOD) δ 174.7, 171.2, 163.2, 156.1, 150.2, 139.0, 126.5, 125.1, 116.3, 75.6, 67.2, 
18.0, 11.9 (d, J = 5.3 Hz) ppm. 
1-[2-(3-fluorophenyl)-6-(thiophen-2-yl)pyrimidin-4-yl]ethane-1,2-diol (8e): orange solid, 71%, Rf  = 
0.75 (CHCl3/MeOH 5:1), UHPLC-ESI-MS: Rt = 2.80 min., m/z = 317.0 [M + H]
 +. 1H NMR (300 
MHz, MeOD) δ 8.29 (d, J = 7.8 Hz, 1H), 8.17 – 8.13 (m, 1H), 7.93 (dd, J = 0.9 Hz, J = 3.7 Hz, 1H), 
7.84 (s, 1H), 7.64 (dd, J = 0.9 Hz, J = 5.0 Hz, 1H), 7.51 – 7.43 (m, 1H), 7.23 – 7.16 (m, 2H), 4.80 (dd, 
J = 3.8 Hz, J = 5.8 Hz, 1H), 4.03 (dd, J = 3.8 Hz, J = 11.3 Hz, 1H), 3.87 (dd, J = 6.0 Hz, J = 11.3 Hz, 
1H) ppm; 13C NMR (100 MHz, MeOD) δ 172.6, 166.1, 163.7 (d, J = 3.2 Hz), 162.9, 161.0, 144.0, 
141.4 (d, J = 7.8 Hz), 131.5, 131.2 (d, J = 8.1 Hz), 129.4 (d, J = 36.2 Hz), 125.1 (d, J = 2.7 Hz), 118.5 
(d, J = 21.6 Hz), 115.8 (d, J = 23.5 Hz), 111.3, 75.8, 67.1 ppm. 
1-[2-propyl-6-(thiophen-2-yl)pyrimidin-4-yl]ethane-1,2-diol (8f): yellow solid, 82%, Rf  = 0.78 
(CHCl3/MeOH 5:1), UHPLC-ESI-MS: Rt = 2.33 min., m/z = 265.2 [M + H]
 +. 1H NMR (300 MHz, 
MeOD) δ 7.90 (d, J = 3.6 Hz, 1H), 7.78 (s, 1H), 7.63 (d, J = 4.9 Hz, 1H), 7.17 (t, J = 4.5 Hz, 1H), 4.72 
– 4.69 (m, 1H), 3.91 (dd, J = 3.8 Hz, J = 11.3 Hz, 1H), 3.75 (dd, J = 6.0 Hz, J = 11.3 Hz, 1H), 2.87 (t, J 
= 7.5 Hz, 2H), 1.90 – 1.82 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H) ppm; 13C NMR (100 MHz, MeOD) δ 
172.1, 171.7, 161.0, 143.9, 131.4, 129.5, 129.1, 110.4, 75.6, 67.2, 41.8, 22.9, 14.2 ppm. 
4.4 General procedures for the synthesis of 2,3,4,6-tetrasubstituted pyridines (Series C) 
Synthesis of 9a-b: to a stirred solution of the corresponding ynone (0.6 eq) and ethyl acetoacetate (1.0 
eq) in EtOH was added NH4OAc (10.0 eq). The mixture was stirred at reflux overnight. Solvent was 
removed under reduced pressure, the crude was redissolved in EtOAc and washed three times with 
NaHCO3 (saturated solution). The organic layer was dried over MgSO4, filtered and concentrated in 
vacuo. The crude was redissolved in ACN (1 mL), filtered and purified by preparative HPLC.53 
ethyl 4-{1,4-dioxaspiro[4.5]decan-2-yl}-2-methyl-6-phenylpyridine-3-carboxylate (9a): brown oil, 
92%, Rf  = 0.53 (CyH/EtOAc 9:1), UHPLC-ESI-MS: Rt = 3.80 min., m/z = 382.2 [M + H]
 +. 1H NMR 
(300 MHz, CDCl3) δ 8.01 (dd, J = 1.5 Hz, J = 8.0 Hz, 2H), 7.87 (s, 1H), 7.51 – 7.43 (m, 3H), 5.22 (t, J 
= 6.9 Hz, 1H), 4.47 – 4.39 (m, 3H), 3.72 (dd, J = 7.2 Hz, J = 8.4 Hz, 1H), 2.68 (s, 3H), 1.88 – 1.81 (m, 
2H), 1.76 – 1.60 (m, 6H), 1.51 – 1.47 (m, 2H), 1.42 (t, J = 7.1 Hz, 3H) ppm; 13C NMR (100 MHz, 
CDCl3) δ 168.2, 158.0, 156.0, 149.2, 138.9, 129.4, 128.8, 127.2, 124.7, 114.4, 110.9, 74.7, 70.9, 61.7, 
35.8, 35.0, 25.2, 24.0, 23.8, 23.7, 14.2 ppm. 
ethyl 6-cyclopropyl-4-{1,4-dioxaspiro[4.5]decan-2-yl}-2-methylpyridine-3-carboxylate (9b): 
brown oil, 87%, Rf  = 0.50 (CyH/EtOAc 9:1), UHPLC-ESI-MS: Rt = 3.42 min., m/z = 346.2 [M + H]
 +. 
1H NMR (300 MHz, CDCl3) δ 7.21 (s, 1H), 5.13 (t, J = 6.9 Hz, 1H), 4.40 – 4.33 (m, 3H), 3.64 (d, J = 
7.8 Hz, 1H), 2.50 (s, 3H), 2.08 – 1.99 (m, 1H), 1.82 – 1.73 (m, 2H), 1.70 – 1.59 (m, 6H), 1.48 – 1.44 
(m, 2H), 1.37 (t, J = 7.1 Hz, 3H), 1.01 – 0.97 (m, 4H) ppm; 13C NMR (100 MHz, CDCl3) δ 168.4, 
164.2, 155.5, 148.1, 123.0, 114.4, 110.6, 74.5, 70.9, 61.4, 35.8, 34.8, 25.1, 23.9, 23.8, 23.6, 17.5, 14.2, 
10.1 ppm. 
Synthesis of 10a-b: a stirred solution of 9a-b in EtOH was cooled to 0 °C using an ice bath. 1 M 
NaOH (3.0 eq) was added dropwise. The mixture was stirred at reflux overnight. Solvent was 
evaporated under reduced pressure, the crude was redissolved in DCM and extracted with water. The 
aqueous layer was acidified with 1M HCl until pH = 1 and extracted three times with CHCl3/i-PrOH 
(7:3). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude was 
redissolved in ACN (1 mL), filtered and purified by preparative HPLC.  
4-{1,4-dioxaspiro[4.5]decan-2-yl}-2-methyl-6-phenylpyridine-3-carboxylic acid (10a): yellow oil, 
80%, Rf  = 0.23 (CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 2.76 min., m/z = 354.2 [M + H]
 +. 1H NMR 
(300 MHz, CDCl3) δ 8.01 (d, J = 7.3 Hz, 2H), 7.92 (s, 1H), 7.53 – 7.43 (m, 3H), 5.34 (t, J = 6.9 Hz, 
1H), 4.46 (t, J = 7.7 Hz, 1H), 3.73 (t, J = 7.6 Hz, 1H), 2.80 (s, 3H), 1.89 – 1.82 (m, 2H), 1.79 – 1.66 (m, 
6H), 1.51 – 1.47 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 171.2, 158.2, 156.5, 150.7, 138.2, 129.7, 
128.8, 127.4, 115.2, 111.0, 74.7, 71.0, 35.8, 34.8, 25.2, 24.0, 23.8, 23.7 ppm. 
6-cyclopropyl-4-{1,4-dioxaspiro[4.5]decan-2-yl}-2-methylpyridine-3-carboxylic acid (10b): yellow 
oil, 83%, Rf  = 0.18 (CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 1.98 min., m/z = 318.2 [M + H]
 +. 1H 
NMR (300 MHz, CDCl3) δ 7.20 (s, 1H), 5.40 (t, J = 6.7 Hz, 1H), 4.46 (t, J = 7.9 Hz, 1H), 3.68 (t, J = 
7.5 Hz, 1H), 2.77 (s, 3H), 2.54 – 2.49 (m, 1H), 1.71 – 1.59 (m, 8H), 1.42 (s, 2H), 1.22 (d, J = 8.1 Hz, 
2H), 1.03 – 1.01 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 169.4, 159.5, 154.1, 151.1, 131.5, 113.9, 
110.8, 74.6, 70.6, 35.8, 34.5, 25.0, 23.9, 23.6, 19.4, 14.4, 11.4, 11.3 ppm. 
Synthesis of 11a-b: a stirred solution of the protected pyridine 10a-b in 1,4-dioxane was cooled to 0 
°C using an ice bath. A catalytic amount of concentrated HCl was added. The reaction was stirred at 
room temperature for 1 – 3 hours. Solvent was evaporated under reduced pressure, the crude was 
redissolved in ACN (1 mL), filtered and purified by preparative HPLC.  
4-(1,2-dihydroxyethyl)-2-methyl-6-phenylpyridine-3-carboxylic acid (11a): white solid, 80%, Rf  = 
0.78 (CHCl3/MeOH 5:1), UHPLC-ESI-MS: Rt = 2.34 min., m/z = 274.1 [M + H]
 +. 1H NMR (300 
MHz, CDCl3) δ 8.07 – 8.03 (m, 2H), 7.67 (s, 1H), 7.50 – 7.48 (m, 3H), 5.51 (t, J = 4.3 Hz, 1H), 4.15 
(dd, J = 3.8 Hz, J = 12.3 Hz, 1H), 3.98 (dd, J = 4.9 Hz, J = 12.3 Hz, 1H), 2.92 (s, 3H) ppm; 13C NMR 
(100 MHz, CDCl3) δ 169.3, 161.0, 159.8, 156.8, 138.1, 130.3, 128.9, 127.7, 118.6, 111.3, 80.3, 63.2, 
21.0 ppm. 
6-cyclopropyl-4-(1,2-dihydroxyethyl)-2-methylpyridine-3-carboxylic acid (11b): yellow oil, 72%, 
Rf  = 0.46 (CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 1.74 min., m/z = 238.2 [M + H]
 +. 1H NMR (300 
MHz, MeOD) δ 7.17 (s, 1H), 5.38 (s, 1H), 3.94 (dd, J = 3.2 Hz, J = 12.3 Hz, 1H), 3.80 (dd, J = 3.8 Hz, 
J = 12.3 Hz, 1H), 2.61 (s, 3H), 2.13 – 2.04 (m, 1H), 0.99 (d, J = 6.9 Hz, 4H) ppm; 13C NMR (100 MHz, 
MeOD) δ 171.5, 169.4, 159.8, 158.5, 118.9, 113.4, 82.3, 63.0, 20.6, 18.7, 11.7 (d, J = 7.9 Hz) ppm. 
4.5 General procedures for the synthesis of 3,5 -disubstituted (Series D) and 1,3,5-trisubstituted 
pyrazoles (series E) 
Synthesis of 12a-g and 13h-o: to a stirred solution of the corresponding ynone (1.0 eq) in EtOH (2 
mL) was added the corresponding hydrazine (hydrazine monohydrated or methyl hydrazine) (1.3 eq). 
The mixture was stirred at room temperature until starting material consumption (monitored by TLC) 
(normally 2 – 3 hours). Solvent was removed under reduced pressure, the crude was redissolved in 
ACN (1 mL), filtered and purified by preparative HPLC.58 
5-{1,4-dioxaspiro[4.5]decan-2-yl}-3-phenyl-1H-pyrazole (12a): yellowish oil, 57%, Rf  = 0.19 
(CyH/EtOAC 3:1), UHPLC-ESI-MS: Rt = 2.94 min., m/z = 285.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 7.65 (d, J = 7.1 Hz, 2H), 7.42 – 7.30 (m, 3H), 6.55 (s, 1H), 5.21 (t, J = 6.6 Hz, 1H), 4.31 (dd, 
J = 6.4 Hz, J = 8.1 Hz, 1H), 3.98 (t, J = 8.1 Hz, 1H), 1.76 – 1.61 (m, 8H), 1.43 – 1.40 (m, 2H) ppm; 13C 
NMR (100 MHz, CDCl3) δ 148.6, 147.9, 130.9, 128.9, 128.3, 125.6, 110.7, 100.5, 71.3, 69.5, 36.1, 
35.2, 25.1, 24.0, 23.8 ppm. 
5-{1,4-dioxaspiro[4.5]decan-2-yl}-3-(furan-2-yl)-1H-pyrazole (12b): brown oil, 49%, Rf  = 0.21 
(CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 2.75 min., m/z = 275.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 7.42 (d, J = 1.3 Hz, 1H), 6.62 (d, J = 3.3 Hz, 1H), 6.47 (s, 1H) 6.44 (dd, J = 1.8 Hz, J = 3.3 
Hz, 1H), 5.21 (t, J = 6.6 Hz, 1H), 4.31 (dd, J = 6.3 Hz, J = 8.3 Hz, 1H), 3.96 (dd, J = 6.9 Hz, J = 8.2 
Hz, 1H), 1.73 – 1.57 (m, 8H), 1.45 – 1.38 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 148.4, 146.5, 
142.1, 139.7, 111.4, 110.7, 106.4, 99.7, 71.1, 69.4, 36.1, 35.2, 25.1, 23.9, 23.8 ppm. 
5-{1,4-dioxaspiro[4.5]decan-2-yl}-3-(thiophen-2-yl)-1H-pyrazole (12c): yellow oil, 63%, Rf  = 0.32 
(CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 2.88 min., m/z = 291.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 7.28 – 7.24 (m, 2H), 7.03 (dd, J = 3.6 Hz, J = 5.1 Hz, 1H), 6.42 (s, 1H), 5.19 (t, J = 6.5 Hz, 
1H), 4.30 (dd, J = 6.3 Hz, J = 8.3 Hz, 1H), 3.95 (dd, J = 6.7 Hz, J = 8.3 Hz, 1H), 1.73 – 1.59 (m, 8H), 
1.44 – 1.38 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 146.9, 144.4, 134.5, 127.6, 125.0, 124.1, 
110.8, 100.4, 70.8, 69.4, 36.1, 35.1, 25.0, 24.0, 23.8 ppm. 
5-{1,4-dioxaspiro[4.5]decan-2-yl}-3-(propan-2-yl)-1H-pyrazole (12d): yellow oil, 68%, Rf  = 0.25 
(CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 2.76 min., m/z = 251.6 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 6.09 (s, 1H), 5.15 (t, J = 7.2 Hz, 1H), 4.27 (dd, J = 6.3 Hz, J = 8.2 Hz, 1H), 3.92 (t, J = 8.1 
Hz, 1H), 2.98 (td, J = 6.9 Hz, J = 13.9 Hz, 1H), 1.74 – 1.59 (m, 8H), 1.43 – 1.40 (m, 2H), 1.27 (d, J = 
6.9 Hz, 6H) ppm; 13C NMR (100 MHz, CDCl3) δ 153.1, 149.4, 110.4, 99.7, 71.8, 69.5, 36.2, 35.3, 26.3, 
25.1, 24.0, 23.8, 22.3 ppm.  
3-cyclopropyl-5-{1,4-dioxaspiro[4.5]decan-2-yl}-1H-pyrazole (12e): yellow oil, 49%, Rf  = 0.12 
(CyH/EtOAC 3:1), UHPLC-ESI-MS: Rt = 2.66 min., m/z = 249.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 5.92 (s, 1H), 5.12 (t, J = 6.8 Hz, 1H), 4.25 (dd, J = 6.3 Hz, J = 8.0 Hz, 1H), 3.89 (t, J = 7.7 
Hz, 1H), 1.90 – 1.81 (m, 1H), 1.68 – 1.60 (m, 8H), 1.43 – 1.39 (m, 2H), 0.96 – 0.89 (m, 2H), 0.72 – 
0.67 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 149.8, 149.1, 110.3, 99.2, 71.8, 69.5, 36.1, 35.2, 
25.1, 23.9, 23.8, 7.6 (d, J = 3.5 Hz), 7.3 ppm. 
3-cyclopentyl-5-{1,4-dioxaspiro[4.5]decan-2-yl}-1H-pyrazole (12f): yellow oil, 75%, Rf  = 0.14 
(CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 3.01 min., m/z = 277.4 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 6.08 (s, 1H), 5.14 (t, J = 7.2 Hz, 1H), 4.27 (dd, J = 6.3 Hz, J = 8.1 Hz, 1H), 3.93 (t, J = 7.8 
Hz, 1H), 3.07 –3.02 (m, 1H), 2.09 – 2.03 (m, 2H), 1.78 – 1.59 (m 14H), 1.44 – 1.40 (m, 2H) ppm; 13C 
NMR (100 MHz, CDCl3) δ 151.2, 149.8, 110.3, 100.1, 72.0, 69.5, 37.2, 36.2, 35.3, 33.0, 25.1, 24.0, 
23.8 ppm. 
3-(adamantan-1-yl)-5-{1,4-dioxaspiro[4.5]decan-2-yl}-1H-pyrazole (12g): brown oil, 80%, Rf  = 
0.28 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 3.51 min., m/z = 343.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 6.08 (s, 1H), 5.14 (dd, J = 6.4 Hz, J = 7.5 Hz, 1H), 4.27 (dd, J = 6.3 Hz, J = 8.1 Hz, 1H), 3.93 
(t, J = 7.9 Hz, 1H), 2.06 (s, 3H), 1.91 (d, J = 2.6 Hz, 6H), 1.75 – 1.62 (m 14H), 1.44 – 1.40 (m, 2H) 
ppm; 13C NMR (100 MHz, CDCl3) δ 155.8, 149.5, 110.3, 98.7, 72.1, 69.5, 42.4, 36.5, 36.2, 35.3, 28.3, 
25.1, 24.0, 23.8 ppm. 
5-{1,4-dioxaspiro[4.5]decan-2-yl}-1-methyl-3-phenyl-1H-pyrazole (13a): yellowish oil, 50%, Rf  = 
0.39 (CyH/EtOAC 3:1), UHPLC-ESI-MS: Rt = 3.22 min., m/z = 299.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 7.74 (d, J = 7.2 Hz, 2H), 7.36 (t, J = 7.4 Hz, 2H), 7.26 (t, J = 7.2 Hz, 1H), 6.48 (s, 1H), 5.14 
(t, J = 6.7 Hz, 1H), 4.31 (dd, J = 6.4 Hz, 1H, J = 8.2 Hz, 1H), 3.94 (s, 3H), 1.66 – 1.60 (m, 8H), 1.44 – 
1.40 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 150.2, 141.5, 133.3, 128.5, 127.6, 125.4, 110.0, 
101.6, 69.2, 68.3, 37.2, 36.1, 35.2, 25.0, 23.9 (d, J = 2.4 Hz) ppm. 
5-{1,4-dioxaspiro[4.5]decan-2-yl}-3-(furan-2-yl)-1-methyl-1H-pyrazole (13b): brown oil, 51%, Rf  
= 0.28 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 2.95 min., m/z = 289.2 [M + H]
 +. 1H NMR (300 
MHz, CDCl3) δ 7.41 (d, J = 1.1 Hz, 1H), 6.60 (d, J = 3.0 Hz, 1H), 6.43 (t, J = 1.8 Hz, 1H), 6.42 (s, 1H) 
5.13 (t, J = 6.6 Hz, 1H), 4.31 (dd, J = 6.3 Hz, J = 8.3 Hz, 1H), 4.05 (dd, J = 6.9 Hz, J = 8.3 Hz, 1H), 
3.93 (s, 3H), 1.69 – 1.58 (m, 8H), 1.42 – 1.38 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 148.7, 
142.7, 141.6, 141.4, 111.2, 110.0, 105.3, 101.3, 69.0, 68.2, 37.2, 36.0, 35.2, 25.0, 23.9, 23.8 ppm. 
5-{1,4-dioxaspiro[4.5]decan-2-yl}-1-methyl-3-(thiophen-2-yl)-1H-pyrazole (13c): yellow oil, 58%, 
Rf  = 0.42 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 3.13 min., m/z = 305.2 [M + H]
 +. 1H NMR (300 
MHz, CDCl3) δ 7.33 (dd, J = 1.0 Hz, J = 3.5 Hz, 1H), 7.27 (dd, J = 1.0 Hz, J = 5.1 Hz, 1H), 7.08 (dd, J 
= 3.6 Hz, J = 5.1 Hz, 1H), 6.46 (s, 1H), 5.19 (t, J = 6.6 Hz, 1H), 4.38 (dd, J = 6.3 Hz, J = 8.3 Hz, 1H), 
4.11 (dd, J = 6.9 Hz, J = 8.3 Hz, 1H), 1.73 – 1.67 (m, 8H), 1.51 – 1.45 (m, 2H) ppm; 13C NMR (100 
MHz, CDCl3) δ 145.5, 141.7, 136.5, 127.3, 124.2, 123.4, 111.0, 101.5, 69.1, 68.2, 37.2, 36.1, 35.2, 
25.0, 23. 9 (d, J = 2.4 Hz) ppm. 
5-{1,4-dioxaspiro[4.5]decan-2-yl}-1-methyl-3-(propan-2-yl)-1H-pyrazole (13d): yellow oil, 71%, Rf  
= 0.55 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 3.01 min., m/z = 265.2 [M + H]
 +. 1H NMR (300 
MHz, CDCl3) δ 6.00 (s, 1H), 5.09 (t, J = 7.2 Hz, 1H), 4.27 (dd, J = 6.3 Hz, J = 8.2 Hz, 1H), 3.98 (t, J = 
7.8 Hz, 1H), 3.85 (s, 3H), 2.92 (td, J = 6.9 Hz, J = 13.9 Hz, 1H), 1.66 – 1.62 (m, 8H), 1.41 – 1.39 (m, 
2H), 1.23 (d, J = 6.9 Hz, 6H) ppm; 13C NMR (100 MHz, CDCl3) δ 158.0, 140.1, 110.7, 101.0, 69.3, 
68.3, 36.7, 36.1, 35.2, 27.8, 25.1, 23.9 (d, J = 4.0 Hz), 22.9 ppm. 
3-cyclopropyl-5-{1,4-dioxaspiro[4.5]decan-2-yl}-1-methyl-1H-pyrazole (13e): yellow oil, 69%, Rf  
= 0.28 (CyH/EtOAC 3:1), UHPLC-ESI-MS: Rt = 2.88 min., m/z = 263.2 [M + H]
 +. 1H NMR (300 
MHz, CDCl3) δ 5.84 (s, 1H), 5.07 (t, J = 6.8 Hz, 1H), 4.26 (dd, J = 6.3 Hz, J = 8.2 Hz, 1H), 3.95 (dd, J 
= 7.4 Hz, J = 8.0 Hz, 1H), 3.82 (s, 3H), 1.91 – 1.82 (m, 1H), 1.64 – 1.60 (m, 8H), 1.41 (d, J = 4.8 Hz, 
2H), 0.90 – 0.84 (m, 2H), 0.69 – 0.64 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 153.8, 140.5, 
110.8, 100.6, 69.2, 68.3, 36.7, 36.1, 35.2, 25.0, 23.9 (d, J = 2.8 Hz), 9.0, 7.7 ppm. 
3-cyclopentyl-5-{1,4-dioxaspiro[4.5]decan-2-yl}-1-methyl-1H-pyrazole (13f): brown oil, 66%, Rf  = 
0.36 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 3.25 min., m/z = 291.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 5.99 (s, 1H), 5.08 (t, J = 6.6 Hz, 1H), 4.26 (dd, J = 6.3 Hz, J = 8.2 Hz, 1H), 3.96 (t, J = 7.8 
Hz, 1H), 3.84 (s, 3H), 3.06 –2.95 (m, 1H), 2.03 – 1.96 (m, 2H), 1.73 – 1.61 (m 14H), 1.43 – 1.38 (m, 
2H) ppm; 13C NMR (100 MHz, CDCl3) δ 156.1, 140.1, 110.7, 101.5, 69.3, 68.3, 39.0, 36.7, 36.1, 35.1, 
33.4, 25.3, 25.0, 23.9 (d, J = 3.9 Hz) ppm. 
3-(adamantan-1-yl)-5-{1,4-dioxaspiro[4.5]decan-2-yl}-1-methyl-1H-pyrazole (13g): brown oil, 
61%, Rf  = 0.55 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 3.78 min., m/z = 357.4 [M + H]
 +. 1H NMR 
(300 MHz, CDCl3) δ 6.02 (s, 1H), 5.09 (t, J = 7.2 Hz, 1H), 4.27 (dd, J = 6.3 Hz, J = 8.2 Hz, 1H), 3.97 
(t, J = 8.1 Hz, 1H), 3.86 (s, 3H), 2.03 – 1.98 (m, 3H), 1.90 (d, J = 2.9 Hz, 6H), 1.75 – 1.73 (m, 6H), 
1.65 – 1.61 (m, 8H), 1.44 – 1.39 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 161.1, 139.7, 110.7, 
100.2, 69.3, 68.3, 42.7, 36.8, 36.1, 35.1, 33.8, 28.6, 25.0, 23.9 (d, J = 4.5 Hz) ppm. 
5-{1,4-dioxaspiro[4.5]decan-2-yl}-1-methyl-3-(3-methylphenyl)-1H-pyrazole (13h): brown oil, 
54%, Rf  = 0.59 (CyH/EtOAC 9:1), UHPLC-ESI-MS: Rt = 3.34 min., m/z = 313.2 [M + H]
 + .1H NMR 
(300 MHz, CDCl3) δ 7.61 (s, 1H), 7.54 (d, J = 7.7 Hz, 1H), 7.29 – 7.24 (m, 1H), 7.10 (d, J = 7.5 Hz, 
1H), 6.49 (s, 1H), 5.17 (t, J = 6.7 Hz, 1H), 4.34 (dd, J = 6.3 Hz, 8.3 Hz, 1H), 4.08 (dd, J = 7.1 Hz, 8.2 
Hz, 1H), 3.97 (s, 3H), 1.72 – 1.60 (m, 8H), 1.44 – 1.41 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 
150.1, 141.4, 138.0, 133.1, 128.3, 128.2, 125.9, 122.5, 110.8, 101.4, 69.1, 68.1, 37.0, 36.0, 35.1, 24.9, 
23.8 (d, J = 3.9 Hz), 21.3 ppm. 
3-(5-{1,4-dioxaspiro[4.5]decan-2-yl}-1-methyl-1H-pyrazol-3-yl)benzonitrile (13i): orange oil, 65%, 
Rf  = 0.30 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 3.14 min., m/z = 324.2 [M + H]
 + .1H NMR (300 
MHz, CDCl3) δ 8.04 (s, 1H), 7.97 (dt, J = 1.5 Hz, J = 8.1 Hz, 1H), 7.54 (dt, J = 1.4 Hz, J = 7.7 Hz, 
1H), 7.45 (t, J = 7.7 Hz, 1H), 6.52 (s, 1H), 5.16 (t, J = 6.6 Hz, 1H), 4.34 (dd, J = 6.3 Hz, J = 8.3 Hz, 
1H), 4.06 (dd, J = 6.9 Hz, J = 8.3 Hz, 1H), 3.96 (s, 3H), 1.70 – 1.59 (m, 8H), 1.45 – 1.39 (m, 2H) ppm; 
13C NMR (100 MHz, CDCl3) δ 147.8, 142.2, 134.6, 130.8, 129.4, 129.3, 128.8, 118.8, 112.7, 111.1, 
101.7, 69.0, 68.2, 37.4, 36.1, 35.0, 25.0, 23.8 (d, J = 4.6 Hz) ppm. 
3-(3-chloro-5-fluorophenyl)-5-{1,4-dioxaspiro[4.5]decan-2-yl}-1-methyl-1H-pyrazole (13j): yellow 
oil, 61%, Rf  = 0.49 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 3.60 min., m/z = 351.0 [M + H]
 + .1H 
NMR (300 MHz, CDCl3) δ 7.54 (s, 1H), 7.36 (d, J = 8.9 Hz, 1H), 6.98 (d, J = 8.3 Hz, 1H), 6.47 (s, 
1H), 5.14 (t, J = 6.6 Hz, 1H), 4.33 (t, J = 7.5 Hz, 1H), 4.05 (t, J = 7.6 Hz, 1H), 3.94 (s, 3H), 1.67 – 1.65 
(m, 8H), 1.42 (d, J = 4.5 Hz, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 162.9 (d, J = 248.2 Hz), 147.7 
(d, J = 2.9 Hz), 142.1, 136.5 (d, J = 9.3 Hz), 135.1 (d, J = 11.0 Hz), 121.3 (d, J = 3.1 Hz), 114.9 (d, J = 
25.0 Hz), 111.1, 110.6 (d, J = 22.8 Hz), 101.8, 69.0, 68.2, 37.3, 36.1, 35.1, 25.0, 23.8 (d, J = 4.0 Hz) 
ppm. 
4-(5-{1,4-dioxaspiro[4.5]decan-2-yl}-1-methyl-1H-pyrazol-3-yl)benzamide (13k): brown oil, 41%, 
Rf  = 0.29 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 2.79 min., m/z = 342.2 [M + H]
 +. 1H NMR (300 
MHz, CDCl3) δ 7.63 (d, J = 8.9 Hz, 2H), 6.74 (d, J = 8.9 Hz, 2H), 6.40 (s, 1H), 5.13 (t, J = 6.7 Hz, 1H), 
4.31 (dd, J = 6.3 Hz, J = 8.2 Hz, 1H), 4.06 (dd, J = 7.2 Hz, J = 8.2 Hz, 1H), 3.92 (s, 3H), 2.96 (s, 6H), 
1.67 – 1.59 (m, 8H), 1.45 – 1.40 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 150.5, 150.0, 141.2, 
126.3, 121.8, 112.5, 110.8, 100.6, 69.1, 68.2, 40.5, 36.9, 36.0, 35.1, 25.0, 23.8 ppm. 
5-(5-{1,4-dioxaspiro[4.5]decan-2-yl}-1-methyl-1H-pyrazol-3-yl)-1,2-oxazole (13l): brown oil, 55%, 
Rf  = 0.17 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 2.74 min., m/z = 290.2 [M + H]
 +. 1H NMR (300 
MHz, CDCl3) δ 8.27 (s, 1H), 6.64 (s, 1H), 6.54 (s, 1H), 5.17 (t, J = 6.5 Hz, 1H), 4.35 (dd, J = 6.9 Hz, J 
= 7.8 Hz, 1H), 4.09 (d, J = 4.6 Hz, 1H), 3.99 (s, 3H), 1.73 – 1.61 (m, 8H), 1.42 (d, J = 4.4 Hz, 2H) 
ppm; 13C NMR (100 MHz, CDCl3) δ 164.1, 150.5, 142.2, 139.4, 111.3, 103.5, 98.6, 68.9, 68.1, 37.7, 
36.0, 35.1, 25.0, 23.9 (d, J = 2.2 Hz) ppm. 
2-(5-{1,4-dioxaspiro[4.5]decan-2-yl}-1-methyl-1H-pyrazol-3-yl)-1H-indole (13m): brown oil, 75%, 
Rf  = 0.77 (CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 3.19 min., m/z = 338.2 [M + H]
 +. 1H NMR (300 
MHz, CDCl3) δ 9.43 (s br, 1H), 7.62 (d, J = 7.7 Hz, 1H), 7.30 (d, J = 8.4 Hz, 1H), 7.17 (td, J = 6.9 Hz, 
J = 15.0 Hz, 1H), 7.10 (td, J = 7.2 Hz, J = 14.7 Hz, 1H), 6.74 (d, J = 1.4 Hz, 1H), 6.56 (s, 1H), 5.16 (t, 
J = 6.6 Hz, 1H), 4.35 (dd, J = 6.4 Hz, J = 8.3 Hz, 1H), 4.10 (dd, J = 6.9 Hz, J = 8.3 Hz, 1H), 3.93 (s, 
3H), 1.71 – 1.65 (m, 8H), 1.49 – 1.45 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 143.8, 141.9, 
136.2, 131.6, 128.8, 122.0, 120.4, 119.7, 111.1, 110.8, 101.9, 99.4, 69.0, 68.1, 37.1, 36.1, 35.1, 25.0, 
23.9 (d, J = 3.4 Hz) ppm. 
3-(5-{1,4-dioxaspiro[4.5]decan-2-yl}-1-methyl-1H-pyrazol-3-yl)pyridine (13n): brown oil, 46%, Rf  
= 0.76 (CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 2.11 min., m/z = 300.2 [M + H]
 +. 1H NMR (300 
MHz, CDCl3) δ 8.97 (s, 1H), 8.52 (d, J = 3.8 Hz, 1H), 8.09 (dt, J = 1.9 Hz, 7.9 Hz, 1H), 7.33 (dd, J = 
4.9 Hz, 7.8 Hz, 1H), 6.55 (s, 1H), 5.18 (t, J = 6.6 Hz, 1H), 4.36 (dd, J = 6.4 Hz, 8.3 Hz, 1H), 4.08 (dd, J 
= 7.0 Hz, 8.3 Hz, 1H), 3.98 (s, 3H), 1.72 – 1.60 (m, 8H), 1.46 – 1.41 (m, 2H) ppm; 13C NMR (100 
MHz, CDCl3) δ 148.4, 147.0, 146.8, 142.0, 132.7, 129.3, 123.5, 111.1, 101.7, 69.1, 68.2, 37.3, 36.1, 
35.1, 25.0, 23.9 (d, J = 4.1 Hz) ppm. 
3-cyclohexyl-5-{1,4-dioxaspiro[4.5]decan-2-yl}-1-methyl-1H-pyrazole (13o): brown oil, 55%, Rf  = 
0.29 (CyH/EtOAC 9:1), UHPLC-ESI-MS: Rt = 3.40 min., m/z = 305.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 5.99 (s, 1H), 5.10 (t, J = 6.9 Hz, 1H), 4.27 (t, J = 8.1 Hz, 1H), 3.98 (t, J = 7.8 Hz, 1H), 3.85 
(s, 3H), 2.61 – 2.54 (m, 1H), 1.94 (d, J = 7.8 Hz, 2H), 1.78 (d, J = 4.5 Hz, 2H), 1.66 – 1.62 (m, 8H), 
1.43 – 1.33 (m, 6H), 1.29 – 1.20 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 157.1, 139.9, 110.7, 
101.2, 69.2, 68.2, 37.5, 36.7, 36.0, 35.1, 33.3, 26.4, 26.1, 25.0, 23.8 (d, J = 3.8 Hz) ppm.  
Synthesis of 14a-g and 15a-g: a stirred solution of the protected pyrazole 12a-g and 13a-g in 1,4-
dioxane was cooled to 0 °C using an ice bath. A catalytic amount of concentrated HCl was added. The 
reaction was stirred at room temperature for 1 – 3 hours. Solvent was evaporated under reduced 
pressure, the crude was redissolved in ACN (1 mL), filtered and purified by preparative HPLC.  
1-(3-phenyl-1H-pyrazol-5-yl)ethane-1,2-diol (14a): yellowish solid, 88%, Rf  = 0.27 (CHCl3/MeOH 
9:1), UHPLC-ESI-MS: Rt = 1.76 min., m/z = 205.4 [M + H]
 +. 1H NMR (300 MHz, MeOD) δ 7.74 – 
7.71 (m, 2H), 7.43 – 7.38 (m, 2H), 7.34 – 7.29 (m, 1H), 6.62 (s, 1H), 4.81 (dd, J = 5.2 Hz, J = 6.6 Hz, 
1H), 3.82 – 3.72 (m, 2H) ppm; 13C NMR (100 MHz, MeOD) δ 151.6, 149.2, 133.0, 129.8, 129.1, 
126.6, 101.2, 69.7, 67.3 ppm. 
1-[3-(furan-2-yl)-1H-pyrazol-5-yl]ethane-1,2-diol (14b): brown oil, 82%, Rf  = 0.29 (CHCl3/MeOH 
9:1), UHPLC-ESI-MS: Rt = 1.50 min., m/z = 195.2 [M + H]
 +. 1H NMR (300 MHz, MeOD) δ 7.53 (s, 
1H), 6.69 (d, J = 3.3 Hz, 1H), 6.50 (d, J = 3.6 Hz, 2H), 4.79 (t, J = 6.3 Hz, 1H), 3.75 (dd, J = 2.5 Hz, J 
= 5.6 Hz, 2H) ppm; 13C NMR (100 MHz, MeOD) δ 150.3, 148.8, 143.4, 141.9, 112.4, 107.1, 100.7, 
69.4, 67.2 ppm. 
1-[3-(thiophen-2-yl)-1H-pyrazol-5-yl]ethane-1,2-diol (14c): yellow oil, 83%, Rf  = 0.27 
(CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 1.68 min., m/z = 211.0 [M + H]
 +. 1H NMR (300 MHz, 
MeOD) δ 7.35 (dd, J = 1.2 Hz, J = 4.3 Hz, 2H), 7.06 (dt, J = 1.3 Hz, J = 4.4 Hz, 1H), 6.49 (s, 1H), 4.80 
(t, J = 5.9 Hz, 1H), 3.76 – 3.74 (m, 2H) ppm; 13C NMR (100 MHz, MeOD) δ 145.7, 145.5, 136.4, 
128.6, 125.8, 125.1, 101.3, 69.2, 67.2 ppm. 
1-[3-(propan-2-yl)-1H-pyrazol-5-yl]ethane-1,2-diol (14d): brown oil, 87%, Rf  = 0.25 (CHCl3/MeOH 
9:1), UHPLC-ESI-MS: Rt = 1.37 min., m/z = 171.2 [M + H]
 +. 1H NMR (300 MHz, MeOD) δ 6.12 (s, 
1H), 4.72 (t, J = 5.9 Hz, 1H), 3.69 (dd, J = 2.8 Hz, J = 4.1 Hz, 2H), 2.98 (td, J = 6.9 Hz, J = 13.8 Hz, 
1H), 1.27 (dd, J = 1.3 Hz, J = 6.9 Hz, 6H) ppm; 13C NMR (100 MHz, MeOD) δ 155.1, 151.9, 100.3, 
70.0, 67.3, 27.6, 22.9 ppm. 
1-(3-cyclopropyl-1H-pyrazol-5-yl)ethane-1,2-diol (14e): yellow oil, 89%, Rf  = 0.16 (CHCl3/MeOH 
9:1), UHPLC-ESI-MS: Rt = 1.22 min., m/z = 169.2 [M + H]
 +. 1H NMR (300 MHz, MeOD) δ 6.25 (s, 
1H), 4.73 (t, J = 5.3 Hz, 1H), 3.62 (d, J = 5.3 Hz, 2H), 2.00 – 1.91 (m, 1H), 1.14 – 1.07 (m, 2H), 0.87– 
0.80 (m, 2H) ppm; 13C NMR (100 MHz, MeOD) δ 152.0, 151.7, 99.9, 69.8, 67.3, 8.4, 8.3 ppm. 
1-(3-cyclopentyl-1H-pyrazol-5-yl)ethane-1,2-diol (14f): brownish solid, 82%, Rf  = 0.23 
(CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 1.68 min., m/z = 197.2 [M + H]
 +. 1H NMR (300 MHz, 
CD3CN) δ 6.01 (s, 1H), 4.63 (t, J = 6.9 Hz, 1H), 3.67 – 3.56 (m, 2H), 3.07 – 3.01 (m, 1H), 2.05 – 1.99 
(m, 2H), 1.77 – 1.71 (m, 2H), 1.66 – 1.54 (m, 4H) ppm; 13C NMR (100 MHz, CD3CN) δ 162.4, 152.0, 
100.4, 69.06, 67.0, 38.1, 33.8, 25.8 ppm. 
1-[3-(adamantan-1-yl)-1H-pyrazol-5-yl]ethane-1,2-diol (14g): brownish solid, 75%, Rf  = 0.25 
(CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 2.24 min., m/z = 263.2 [M + H]
 +. 1H NMR (300 MHz, 
MeOD) δ 6.08 (s, 1H), 4.71 (dd, J = 5.0 Hz, J = 7.0 Hz, 1H), 3.70 (dd, J = 2.7 Hz, J = 6.0 Hz, 2H), 
2.04 (s, 3H), 1.95 (d, J = 2.7 Hz, 6H), 1.81 (s, 6H) ppm; 13C NMR (100 MHz, MeOD) δ 157.5. 152.0, 
99.2, 70.3, 67.4, 43.5, 37.7, 34.3, 30.0 ppm. 
1-(1-methyl-3-phenyl-1H-pyrazol-5-yl)ethane-1,2-diol (15a): yellowish solid, 79%, Rf  = 0.41 
(CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 1.88, m/z = 219.1 [M + H]
 +. 1H NMR (300 MHz, MeOD) 
δ 7.74 (d, J = 7.3 Hz, 2H), 7.37 (t, J = 7.2 Hz, 2H), 7.29 (d, J = 7.4 Hz, 1H), 6.62 (s, 1H), 4.82 (t, J = 
5.8 Hz, 1H), 3.94 (s, 3H), 3.82 (s, 2H) ppm; 13C NMR (100 MHz, MeOD) δ 151.6, 146.4, 134.6, 129.7, 
128.8, 126.6, 102.5, 67.6, 66.4, 37.2 ppm. 
1-[3-(furan-2-yl)-1-methyl-1H-pyrazol-5-yl]ethane-1,2-diol (15b): brown oil, 85%, Rf  = 0.42 
(CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 1.57 min., m/z = 209.2 [M + H]
 +. 1H NMR (300 MHz, 
MeOD) δ 7.50 (d, J = 1.7 Hz, 1H), 6.65 (d, J = 3.3 Hz, 1H), 6.51 (s, 1H), 6.48 (dd, J = 1.8 Hz, J = 3.3 
Hz, 1H), 4.80 (t, J = 6.1 Hz, 1H), 3.92 (s, 3H), 3.80 (dd, J = 4.1 Hz, J = 6.1 Hz, 2H) ppm; 13C NMR 
(100 MHz, MeOD) δ 150.0, 146.2, 143.9, 143.1, 112.3, 106.6, 102.2, 67.5, 66.3, 37.2 ppm. 
1-[1-methyl-3-(thiophen-2-yl)-1H-pyrazol-5-yl]ethane-1,2-diol (15c): yellow oil, 76%, Rf  = 0.44 
(CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 1.76 min., m/z = 225.2 [M + H]
 +. 1H NMR (300 MHz, 
MeOD) δ 7.33 – 7.30 (m, 2H), 7.04 (dd, J = 3.6 Hz, J = 5.1 Hz, 1H), 6.51 (s, 1H), 4.80 (t, J = 6.1 Hz, 
1H), 3.90 (s, 3H), 3.81 (dd, J = 3.8 Hz, J = 6.1 Hz, 2H) ppm; 13C NMR (100 MHz, MeOD) δ 146.7, 
146.4, 137.4, 128.5, 125.4, 124.8, 102.4, 67.5, 66.3, 37.1 ppm. 
1-[1-methyl-3-(propan-2-yl)-1H-pyrazol-5-yl]ethane-1,2-diol (15d): brown oil, 77%, Rf  = 0.47 
(CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 1.50 min., m/z = 185.2 [M + H]
 +. 1H NMR (300 MHz, 
MeOD) δ 6.09 (s, 1H), 4.74 (t, J = 6.0 Hz, 1H), 3.83 (s, 3H), 3.75 (dd, J = 4.4 Hz, J = 6.2 Hz, 2H), 2.98 
(td, J = 6.9 Hz, J = 13.9 Hz, 1H), 1.22 (d, J = 7.0 Hz, 6H) ppm; 13C NMR (100 MHz, MeOD) δ 159.1, 
145.3, 101.6, 67.5, 66.3, 36.6, 28.9, 23.3 ppm. 
1-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)ethane-1,2-diol (15e): yellow oil, 92%, Rf  = 0.36 
(CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 1.37 min., m/z = 183.2 [M + H]
 +. 1H NMR (300 MHz, 
MeOD) δ 6.40 (s, 1H), 4.87 (t, J = 5.8 Hz, 1H), 4.05 (s, 3H), 3.83 (dd, J = 5.4 Hz, J = 11.3 Hz, 1H), 
3.74 (dd, J = 6.1 Hz, J = 11.2 Hz, 1H), 2.10 – 2.01 (m, 1H), 1.25 – 1.18 (m, 2H), 0.97– 0.91 (m, 2H) 
ppm; 13C NMR (100 MHz, MeOD) δ 155.0, 146.4, 101.4, 67.5, 66.3, 36.7, 9.5, 8.4 ppm.  
1-(3-cyclopentyl-1-methyl-1H-pyrazol-5-yl)ethane-1,2-diol (15f): brownish solid, 78%, Rf  = 0.28 
(CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 1.79, m/z = 211.2 [M + H]
 +. 1H NMR (300 MHz, MeOD) 
δ 6.08 (s, 1H), 4.74 (t, J = 6.2 Hz, 1H), 3.82 (s, 3H), 3.75 (dd, J = 4.4 Hz, J = 6.2 Hz, 2H), 3.06 – 2.97 
(m, 1H), 2.03 – 1.96 (m, 2H), 1.79 – 1.75 (m, 2H), 1.72 – 1.60 (m, 4H) ppm; 13C NMR (100 MHz, 
MeOD) δ 157.3, 145.3, 102.1, 67.5, 66.3, 40.2, 36.6, 34.5, 26.2 ppm. 
1-[3-(adamantan-1-yl)-1-methyl-1H-pyrazol-5-yl]ethane-1,2-diol (15g): brownish solid, 67%, Rf  = 
0.50 (CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 2.37 min., m/z = 277.2 [M + H]
 +. 1H NMR (300 
MHz, MeOD) δ 6.10 (s, 1H), 4.74 (t, J = 6.2 Hz, 1H), 3.83 (s, 3H) 3.75 (dd, J = 4.3 Hz, J = 6.1 Hz, 
2H), 2.03 (s, 3H), 1.93 (d, J = 2.7 Hz, 6H), 1.80 (s, 6H) ppm; 13C NMR (100 MHz, MeOD) δ 162.2, 
144.8, 100.9, 67.6, 66.4, 43.9, 38.0, 36.5, 35.0, 30.2 ppm. 
Synthesis of 16a-f: to a stirred solution of 6a (1.0 eq) in EtOH (2 mL) was added the corresponding 
hydrazine (1.3 eq). The mixture was stirred at room temperature until starting material consumption 
(monitored by TLC) (normally 2 – 3 hours). Solvent was removed under reduced pressure, the crude 
was redissolved in ACN (1 mL), filtered and purified by preparative HPLC.58 
5-{1,4-dioxaspiro[4.5]decan-2-yl}-1-ethyl-3-phenyl-1H-pyrazole (16a): orange oil, 44%, Rf = 0.32 
(CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 3.36 min., m/z = 313.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 7.79 – 7.76 (m, 2H), 7.40 – 7.35 (m, 2H), 7.31 – 7.28 (m, 1H), 6.49 (s, 1H), 5.17 (t, J = 6.7 
Hz, 1H), 4.34 (dd, J = 6.3 Hz, J = 8.2 Hz, 1H), 4.27 (dd, J = 3.6 Hz, J = 7.2 Hz, 2H), 4.09 (dd, J = 7.2 
Hz, J = 8.1 Hz, 1H), 1.70 – 1.62 (m, 8H), 1.51 (t, J = 7.2 Hz, 3H), 1.46 – 1.38 (m, 2H) ppm; 13C NMR 
(100 MHz, CDCl3) δ 150.3, 140.8, 133.5, 128.5, 127.5, 125.5, 110.9, 101.3, 69.0, 68.5, 45.0, 36.1, 
35.2, 25.1, 23.9, 16.0 ppm. 
5-{1,4-dioxaspiro[4.5]decan-2-yl}-3-phenyl-1-(propan-2-yl)-1H-pyrazole (16b): brown oil, 60%, Rf  
= 0.78 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 3.60 min., m/z = 327.2 [M + H]
 +. 1H NMR (300 
MHz, CDCl3) δ 7.80 (d, J = 7.2 Hz, 2H), 7.38 (t, J = 7.5 Hz, 2H), 7.29 – 7.26 (m, 1H), 6.47 (s, 1H), 
5.20 (t, J = 7.5 Hz, 1H), 4.69 – 4.61 (m, 1H), 4.34 (dd, J = 6.4 Hz, J = 8.1 Hz, 1H), 4.10 (t, J = 7.5 Hz, 
1H), 1.69 – 1.63 (m, 8H), 1.56 (dd, J = 6.7 Hz, J = 8.7 Hz, 6H), 1.46 – 1.42 (m, 2H) ppm; 13C NMR 
(100 MHz, CDCl3) δ 149.9, 140.2, 133.8, 128.5, 127.3, 125.5, 110.8, 100.8, 69.0, 68.4, 50.9, 36.2, 
35.3, 25.1, 23.9, 22.8 (d, J = 1.8 Hz) ppm. 
1-cyclopropyl-5-{1,4-dioxaspiro[4.5]decan-2-yl}-3-phenyl-1H-pyrazole (16c): yellow oil, 54%, Rf  = 
0.74 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 3.82 min., m/z = 325.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 7.89 (dd, J = 1.6 Hz, J = 8.0 Hz, 2H), 7.47 – 7.39 (m, 3H), 6.89 (s, 1H), 5.66 (t, J = 5.7 Hz, 
1H), 4.51 (dd, J = 7.0 Hz, J = 8.6 Hz, 1H), 3.82 (dd, J = 5.5 Hz, J = 8.6 Hz, 1H), 3.35 – 3.30 (m, 1H), 
1.84 – 1.79 (m, 2H), 1.74 – 1.63 (m, 6H), 1.50 – 1.45 (m, 2H), 1.27 – 1.24 (m, 2H), 1.18 – 1.14 (m, 
2H) ppm; 13C NMR (100 MHz, CDCl3) δ 154.0, 149.0, 131.9, 129.1, 128.7, 126.3, 110.7, 106.4, 72.5, 
69.7, 36.1, 34.5, 25.2, 24.1, 23.8, 11.5 (d, J = 3.1 Hz) ppm. 
3-(5-{1,4-dioxaspiro[4.5]decan-2-yl}-3-phenyl-1H-pyrazol-1-yl)propanenitrile (16d): orange oil, 
41%, Rf  = 0.28 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 3.15, m/z = 338.2 [M + H]
 +. 1H NMR (300 
MHz, CDCl3) δ 7.76 (d, J = 7.4 Hz, 2H), 7.40 (t, J = 7.3 Hz, 2H), 7.33 (d, J = 7.2 Hz, 1H), 6.48 (s, 1H), 
5.22 (t, J = 6.6 Hz, 1H), 4.65 – 4.48 (m, 2H), 4.39 (t, J = 7.5 Hz, 1H), 4.16 (t, J = 7.6 Hz, 1H), 3.04 (dd, 
J = 7.2 Hz, J = 14.3 Hz, 2H), 1.69 – 1.55 (m, 8H), 1.44 (d, J = 4.8 Hz, 2H) ppm; 13C NMR (100 MHz, 
CDCl3) δ 151.5, 141.8, 132.7, 128.7, 128.0, 125.6, 117.1, 111.4, 102.0, 68.8, 68.2, 45.5, 36.1, 35.0, 
25.0, 24.0, 23.9, 19.1 ppm. 
1-cyclopentyl-5-{1,4-dioxaspiro[4.5]decan-2-yl}-3-phenyl-1H-pyrazole (16e): yellow oil, 70%, Rf  = 
0.59 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 3.84 min., m/z = 353.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 7.81 – 7.78 (m, 2H), 7.37 (t, J = 7.5 Hz, 2H), 7.29 – 7.24 (m, 1H), 6.48 (s, 1H), 5.22 (t, J = 
6.7 Hz, 1H), 4.82 – 4.72 (m, 1H), 4.34 (dd, J = 6.3 Hz, J = 8.2 Hz, 1H), 4.09 (dd, J = 7.3 Hz, J = 8.0 
Hz, 1H), 2.24 – 2.11 (m, 3H), 2.09 – 1.98 (m, 3H), 1.72 – 1.61 (m, 10H), 1.46 – 1.43 (m, 2H) ppm; 13C 
NMR (100 MHz, CDCl3) δ 149.7, 141.0, 133.8, 128.4, 127.3, 125.5, 110.8, 100.9, 69.2, 68.5, 60.0, 
36.2, 35.3, 33.1 (d, J = 5.8 Hz), 25.1, 24.7 (d, J = 6.2 Hz), 23.9 (d, J = 0.9 Hz) 8 ppm. 
5-{1,4-dioxaspiro[4.5]decan-2-yl}-1,3-diphenyl-1H-pyrazole (16f): brown oil, 55%, Rf  = 0.81 
(CyH/EtOAC 9:1), UHPLC-ESI-MS: Rt = 3.56 min., m/z = 361.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 7.33 – 7.20 (m, 10H), 6.58 (s, 1H), 5.27 (dd, J = 6.4 Hz, 7.4 Hz, 1H), 4.38 (dd, J = 6.3 Hz, 
8.2 Hz, 1H), 4.07 (t, J = 7.8 Hz, 1H), 1.79 – 1.59 (m, 8H), 1.48 – 1.41 (m, 2H) ppm; 13C NMR (100 
MHz, CDCl3) δ 152.1, 144.1, 139.9, 130.4, 128.8, 128.7, 128.4, 128.2, 127.4, 125.2, 110.4, 105.6, 72.4, 
69.6, 36.2, 35.3, 25.1, 24.0, 23.8 ppm. 
Synthesis of 18: The compound was synthesized following the general procedure for the synthesis of 
ynones (using benzoylchloride and the corresponding terminal alkyne) and pyrazoles (using 
methylhydrazine). 
1,5-dimethyl-3-phenyl-1H-pyrazole (18): brownish oil, 90%, Rf  = 0.38 (CyH/EtOAc 3:1), UHPLC-
ESI-MS: Rt = 2.50 min., m/z = 173.2 [M + H]
 +. 1H NMR (300 MHz, CDCl3) δ 7.78 (d, J = 7.8 Hz, 
2H), 7.39 (d, J = 7.6 Hz, 2H), 7.30 (d, J = 7.3 Hz, 1H), 6.33 (s, 1H), 3.81 (s, 3H), 2.29 (s, 3H) ppm; 13C 
NMR (100 MHz, CDCl3) δ 149.8, 139.6, 133.6, 128.4. 127.2, 125.3, 102.4, 36.0, 11.1 ppm. 
Synthesis of 20a-d: to 1 (1.0 eq) was added the corresponding ketone (3.0 eq) and a catalytic amount 
of p-TSA was added. The reaction was stirred at room temperature overnight. The solvent was 
removed under reduced pressure and the crude was re-dissolved in Et2O and washed three times with 
NaHCO3. The organic layer was dried over MgSO4, filtered and concentrated in vacuo to yield the 
corresponding terminal alkynes. The products were used without being purified. 
2-ethynyl-1,4-dioxaspiro[4.4]nonane (20a): yellowish oil, 76%, Rf  = 0.55 (CyH/EtOAC 9:1), 
UHPLC-ESI-MS: Rt = 3.02 min., m/z = 285.2 [M + H]
 +. 1H NMR (300 MHz, CDCl3) δ 4.65 (dt, J = 
2.1 Hz, J = 6.5 Hz, 1H), 4.13 (dd, J = 6.6 Hz, J = 8.0 Hz, 1H), 3.86 (dd, J = 6.4 Hz, J = 8.0 Hz, 1H), 
2.48 (d, J = 2.1 Hz, 1H), 1.98 – 1.89 (m, 1H), 1.86 – 1.84 (m, 1H), 1.81 – 1.75 (m, 2H), 1.73 – 1.64 (m, 
4H) ppm; 13C NMR (100 MHz, CDCl3) δ 120.2, 81.4, 73.9, 69.8, 64.8, 36.3, 36.1, 23.6, 23.3 ppm. 
2-ethynyl-1,4-dioxaspiro[4.6]undecane (20b): yellowish oil, 82%, Rf  = 0.48 (CyH/EtOAC 9:1), 
UHPLC-ESI-MS: Rt = 3.36 min., m/z = 313.2 [M + H]
 +. 1H NMR (300 MHz, CDCl3) δ 4.64 (d, J = 6.0 
Hz, 1H), 4.11 (t, J = 7.5 Hz, 1H), 3.87 (t, J = 7.2 Hz, 1H), 2.47 (s, 1H), 1.94 (d, J = 4.5 Hz, 2H), 1.78 
(d, J = 7.4 Hz, 2H), 1.55 (s, 8H) ppm; 13C NMR (100 MHz, CDCl3) δ 115.2, 81.4, 73.8, 69.3, 64.8, 
38.9, 38.7, 29.3, 29.2, 22.4, 22.3 ppm. 
2-ethynyl-1,4,8-trioxaspiro[4.5]decane (20c): yellowish oil, 68 %, Rf  = 0.33 (CyH/EtOAc 9:1), 
UHPLC-ESI-MS: Rt = 2.58 min., m/z = 301.2 [M + H]
 +. 1H NMR (300 MHz, CDCl3) δ 4.75 (t, J = 6.1 
Hz, 1H), 4.18 (t, J = 6.9 Hz, 1H), 3.98 (t, J = 7.8 Hz, 1H), 3.83 – 3.72 (m, 4H), 2.50 (s, 1H), 1.95 – 
1.83 (m, 2H), 1.73 (d, J = 3.5 Hz, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 108.2, 81.3, 74.1, 69.6, 
65.9 (d, J = 3.7 Hz), 65.1, 36.5, 36.2 ppm. 
1-{2-ethynyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl}ethan-1-one (20d): yellowish oil, 72%, Rf  = 0.46 
(CyH/EtOAC 1:3), UHPLC-ESI-MS: Rt = 2.40 min., m/z = 342.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 4.75 – 4.73 (m, 1H), 4.17 (dd, J = 6.3 Hz, J = 8.1 Hz, 1H), 3.96 (dd, J = 5.9 Hz, J = 8.1 Hz, 
1H), 3.70 – 3.63 (m, 2H), 3.54 – 3.48 (m, 2H), 2.50 (d, J = 1.9 Hz, 1H), 2.07 (s, 3H), 1.87 – 1.77 (m, 
2H), 1.69 – 1.62 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 168.7, 108.8, 81.0 (d, J = 13.2 Hz), 74.3 
(d, J = 9.1 Hz), 69.7, 65.2, 44.1, 39.3, 35.8 (d, J = 22.0 Hz), 34.9 (d, J = 24.3 Hz), 21.3 ppm. 
Synthesis of 22a-d: to a stirred solution of the corresponding ynone (1.0 eq) in EtOH (2 mL) was 
added methyl hydrazine (1.3 eq). The mixture was stirred at room temperature until starting material 
consumption (monitored by TLC) (normally 2 – 3 hours). Solvent was removed under reduced 
pressure, the crude was redissolved in ACN (1 mL), filtered and purified by preparative HPLC.58 
5-{1,4-dioxaspiro[4.4]nonan-2-yl}-1-methyl-3-phenyl-1H-pyrazole (22a): orange oil, 69%, Rf  = 
0.38 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 3.02, m/z = 285.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 7.77 (d, J = 7.2, 2H), 7.37 (d, J = 7.7 Hz, 2H), 7.30 – 7.25 (m, 1H), 6.51 (s, 1H), 5.09 (t, J = 
6.7 Hz, 1H), 4.26 (dd, J = 6.8 Hz, J = 8.1 Hz, 1H), 4.01 (dd, J = 7.0 Hz, J = 8.0 Hz, 1H), 3.92 (s, 3H), 
1.90 – 1.84 (m, 4H), 1.73 – 1.68 (m, 4H) ppm; 13C NMR (100 MHz, CDCl3) δ 150.0, 141.3, 133.2, 
128.4, 127.4, 125.3, 120.0, 101.6, 69.1, 68.4, 37.0, 36.4, 36.1, 23.4, 23.3 ppm. 
5-{1,4-dioxaspiro[4.6]undecan-2-yl}-1-methyl-3-phenyl-1H-pyrazole (22b): orange oil, 57%, Rf  = 
0.48 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 3.36, m/z = 313.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 7.76 (d, J = 7.6 Hz, 2H), 7.38 (t, J = 7.5 Hz, 2H), 7.29 (d, J = 7.4 Hz, 1H), 6.50 (s, 1H), 5.11 
(t, J = 6.7 Hz, 1H), 4.29 (t, J = 7.8 Hz, 1H), 4.01 (t, J = 7.7 Hz, 1H), 3.95 (s, 3H), 1.97 – 1.83 (m, 4H), 
1.65 – 1.58 (m, 8H) ppm; 13C NMR (100 MHz, CDCl3) δ 150.1, 141.2, 133.2, 128.5, 127.5, 125.4, 
114.9, 101.6, 69.1, 68.1, 34.9, 38.3, 37.2, 29.2 (d, J = 5.7 Hz), 22.4 (d, J = 7.2 Hz) ppm. 
1-methyl-3-phenyl-5-{1,4,8-trioxaspiro[4.5]decan-2-yl}-1H-pyrazole (22c): brown oil, 85%, Rf  = 
0.27 (CyH/EtOAc 3:1), UHPLC-ESI-MS: Rt = 2.58, m/z = 301.2 [M + H]
 +. 1H NMR (300 MHz, 
CDCl3) δ 7.77 – 7.75 (m, 2H), 7.38 (t, J = 7.4 Hz, 2H), 7.30 (d, J = 7.3 Hz, 1H), 6.50 (s, 1H), 5.20 (t, J 
= 6.6 Hz, 1H), 4.37 (dd, J = 6.3 Hz, J = 8.4 Hz, 1H), 4.14 (dd, J = 6.8 Hz, J = 8.4 Hz, 1H), 3.96 (s, 3H), 
3.82 – 3.75 (m, 4H), 1.85 – 1.78 (m, 4H) ppm; 13C NMR (100 MHz, CDCl3) δ 150.2, 141.1, 133.1, 
128.5, 127.6, 125.4, 108.0, 101.4, 69.3, 68.2, 65.9 (d, J = 3.7 Hz), 37.2, 36.9, 36.1 ppm. 
1-[2-(1-methyl-3-phenyl-1H-pyrazol-5-yl)-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]ethan-1-one (22d): 
yellow oil, 44%, Rf  = 0.66 (CHCl3/MeOH 9:1), UHPLC-ESI-MS: Rt = 2.40, m/z = 342.2 [M + H]
 +. 1H 
NMR (300 MHz, CDCl3) δ 7.76 (d, J = 7.6 Hz, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.31 (d, J = 7.2 Hz, 1H), 
6.51 (s, 1H), 5.23 (dd, J = 6.1 Hz, J = 10.9 Hz, 1H), 4.40 (t, J = 6.8 Hz, 1H), 4.17 (dd, J = 7.1 Hz, J = 
14.6 Hz, 1H), 3.97 (s, 3H), 3.74 – 3.68 (m, 2H), 3.59 – 3.51 (m, 2H), 2.12 (d, J = 5.6 Hz, 3H), 1.83 – 
1.74 (m, 4H) ppm; 13C NMR (100 MHz, CDCl3) δ 169.0, 150.3, 141.1, 132.9, 128.6, 127.8, 125.5, 
108.7, 101.4, 69.5 (d, J = 11.7 Hz), 68.4 (d, J = 5.7 Hz), 44.2 (d, J = 4.1 Hz), 39.5, 35.6 (d, J = 3.6 Hz), 
21.3 ppm. 
4.2  Biology 
LsrK overexpression and purification 
LsrK from S. typhimurium was overexpressed in E. coli MET1158 [E. coli, amp resistance, BL21 
(DE3) luxS-, with pMET1144 (lsrK-His in pET21b)]59, kindly donated by Prof. Karina Xavier 
(Instituto Gulbenkian de Ciência, Portugal), according to a previously reported protocol.54 
Primary screening and dose response experiments 
Each compound was initially tested against LsrK at 200 µM. Compounds were plated in triplicate and 
300 nM LsrK, 300 µM (S)-DPD and 100 µM ATP, diluted in assay buffer (25 mM triethanolamine, pH 
7.4, 200 µM MgCl2 and 0.1 mg/mL BSA). After 15mintes of incubation, Kinase Glo Luminescence 
kit´s (Promega, USA) reagent was added according to manufacturer´s instructions. Luminescence was 
recorded after 30 minutes with Varioskan LUX plate reader (Thermo Fisher Scientific, Finland). 
Compounds showing an inhibition > 40 % were tested in a dose-response experiment against LsrK at 6 
different concentrations (25µM – 500 µM). The assay was carried out as reported above, except for the 
addition of Triton X-100 to the assay buffer to prevent potential aggregation. IC50 values were 
determined using the four parameters logistic function in Origin 8.6. 
Glycerokinase assay 
Compounds active against LsrK were also tested against glycerokinase to evaluate their selectivity. 0.3 
U/mL glycerokinase from E. coli (Sigma-Aldrich, USA) and 300 µM glycerol were added to plate 
followed by 100 µM ATP. The assay was performed according to the LsrK inhibition assay protocol. 
4.3 Molecular Modelling 
All the computations were carried out using Schrödinger suite 2018-1.60 The crystal structure of LsrK 
(5YA1) was downloaded from RCSB PDB. The protein structure was prepared using protein 
preparation wizard of Schrödinger so that both ATP and substrate were included in the process. 
Hydrogens were added to the structure using default settings. Missing loops and side chains (residues 
363-372, located far away from the active site) were filled using Prime. Water molecules more than 5Å 
away from the ATP and substrate atoms were deleted. Hetero atom ionization states were generated, 
optimized and then minimized. The active site was defined for grid generation for docking based on the 
substrate coordinates. All synthesized compounds were prepared suing Ligprep module in Schrödinger. 
Ionization states were generated using Epik. Tautomers and stereoisomers were generated retaining the 
specified chiralities. Prepared ligands and protein were used as input for docking in Glide module of 
Schrödinger. Docking was done using standard precision mode in Glide.  
 
ABBREVIATIONS 
(2R,4S)-2,4-dihydroxy-2-methyldihydrofuran-3-one  R-DHMF 
(2R,4S)-2-methyl-2,3,3,4-tetrahydroxytetrahydrofuran  R-THMF 
(2S,4S)-2,4-dihydroxy-2-methyldihydrofuran-3-one  S-DHMF 
(2S,4S)-2-methyl-2,3,3,4-tetrahydroxytetrahydrofuran  S-THMF 
(2S,4S)-2-methyl-2,3,3,4-tetrahydroxytetrahydrofuranborate  S-THMF-borate 
2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl Sphos 
3,4,4-trihydroxy-2-pentanone-5-phosphate  P-TPO 
4,5-dihydroxy-2,3-pentanedione DPD 
Acetonitrile ACN 
Ammonium acetate NH4OAc 
Autoinducer-2 AI-2 
Autoinducers  AIs 
Bis(acetonitrile)dichloropalladium(II) PdCl2(CH3CN)2 
Bis(triphenylphosphine)palladium(II) dichloride PdCl2(PPh3)2 
Broad br 
Carbon nuclear magnetic resonance 13C NMR 
Cesium carbonate Cs2CO3 
Copper iodide CuI 
Deuterated chloroform CDCl3 
Deuterated methanol MeOD 
Diethyl ether Et2O 
Dihydroxyacetone phosphate  DHAP 
DPD-inspired heterocycles  DPD-IHs 
Doublet d 
Doublet of doublets dd 
Doublet of triplets dt 
Ethanol EtOH 
Hydrochloric acid HCl 
Id est i.e. 
LuxS regulated Lsr 
Magnesium chloride MgCl2 
Magnesium sulphate MgSO4 
Methanol MeOH 
Methylhydrazine MeNHNH2 
Micromolar µM 
Microwave mW 
Milligram mg 
N-acyl homoserine lactones AHLs 
Palladium acetate Pd(OAc)2 
para-toluen sulfonic acid p-TSA 
Potassium acetate KOAc 
Protein Data Bank PDB 
Proton nuclear meagnetic resonance 1H NMR 
rt Room temperature 
Rt Retention time 
Quorum Sensing QS 
Quorum Sensing inhibitors QSI 
S-3,3,4,5-tetrahydroxy-2-pentanone S-THP 
S-3,3,4,5-tetrahydroxy-2-pentanone-5-phosphate  P-DPD 
S-4,5-dihydroxy-2,3-pentanedione  S-DPD 
S-adenosylmethionine  SAM 
S-adenosylhomocysteine SAH 
Sodium carbonate decahydrated Na2CO3*10H2O 
Sodium hydroxide NaOH 
S-ribosylhomocisteine SRH 
Triethylamine Et3N 
Triplet of doublet td 
Triphenylphosphine PPh3 
Corresponding Author 
Simona Collina: simona.collina@unipv.it; Tel.: (+39) 0382-987379 
 
Present Address 
§ Current address: DE Shaw Research, 120W 45th Street, 10036, New York, NY 
Author Contributions 
Conceptualization, S.S., F.G and S.C.; Methodology, S.S., F.G.; Investigation, S.S., V.G., M.P., 
F.G., S.C., P.T., P.M., T.L., A.P.; Resources, A.P., P.T.; Writing-Original Draft Preparation, S.S., 
V.G., P.T., P.M., A.P.; Writing-Review & Editing, S.S., F.G., P.T., A.P., S.C.; Supervision, S.C.; 
Project Administration, A.K., P.T., A.P.; Funding Acquisition, F.G., P.T., A.P. 
Funding Sources 
This research was funded by the European Union’s Horizon 2020 research and innovation 
programme INTEGRATE under the Marie Sklodowska Curie grant agreement N°. 642620. 
The authors declare no competing financial interest 
ACKNOWLEDGMENT 
Martyna Bielska, Xenia Iwanova, Virginia Llemos and Eduard Ackerman are acknowledged for 
technical assistance. 
Supporting Information availability: a supporting information file containing figures and NMRs is 
available. Molecular Formula Strings as .csv file is also available. 
  
References 
(1)  Surette, M. G.; Miller, M. B.; Bassler, B. L. Quorum Sensing in Escherichia Coli, Salmonella 
Typhimurium, and Vibrio Harveyi: A New Family of Genes Responsible for Autoinducer 
Production. Proc. Natl. Acad. Sci. U. S. A. 1999, 96 (4), 1639–1644. 
(2)  Waters, C. M.; Bassler, B. L. Quorum Sensing: Cell-to-Cell Communication in Bacteria. Annu. 
Rev. Cell Dev. Biol. 2005, 21, 319–346. 
(3)  Bassler, B. L.; Losick, R. Bacterially Speaking. Cell 2006, 125 (2), 237–246.  
(4)  Lowery, C. A.; Dickerson, T. J.; Janda, K. D. Interspecies and Interkingdom Communication 
Mediated by Bacterial Quorum Sensing. Chem. Soc. Rev. 2008, 37 (7), 1337–1346.  
(5)  Ng, W.-L.; Bassler, B. L. Bacterial Quorum-Sensing Network Architectures. Annu. Rev. Genet. 
2009, 43 (1), 197–222.  
(6)  Davies, D. G.; Parsek, M. R.; Pearson, J. P.; Iglewski, B. H.; Costerton, J. W.; Greenberg, E. P. 
The Involvement of Cell-to-Cell Signals in the Development of a Bacterial Biofilm. Science 
1998, 280 (5361), 295–298. 
(7)  Rickard, A. H.; Palmer, R. J.; Blehert, D. S.; Campagna, S. R.; Semmelhack, M. F.; Egland, P. 
G.; Bassler, B. L.; Kolenbrander, P. E. Autoinducer 2: A Concentration-Dependent Signal for 
Mutualistic Bacterial Biofilm Growth. Mol. Microbiol. 2006, 60 (6), 1446–1456.  
(8)  Irie, Y.; Parsek, M. R. Quorum Sensing and Microbial Biofilms. Curr. Top. Microbiol. Immunol. 
2008, 322, 67–84. 
(9)  Ahmed, N. A. A. M.; Petersen, F. C.; Scheie, A. A. AI-2 Quorum Sensing Affects Antibiotic 
Susceptibility in Streptococcus Anginosus. J. Antimicrob. Chemother. 2007, 60 (1), 49–53.  
(10)  Suga, H.; Smith, K. M. Molecular Mechanisms of Bacterial Quorum Sensing as a New Drug 
Target. Curr. Opin. Chem. Biol. 2003, 7 (5), 586–591.  
(11)  Geske, G. D.; Wezeman, R. J.; Siegel, A. P.; Blackwell, H. E. Small Molecule Inhibitors of 
Bacterial Quorum Sensing and Biofilm Formation. J. Am. Chem. Soc. 2005, 127 (37), 12762–
12763 
(12)  Rasmussen, T. B.; Givskov, M. Quorum-Sensing Inhibitors as Anti-Pathogenic Drugs. Int. J. 
Med. Microbiol. 2006, 296 (2–3), 149–161.  
(13)  Clatworthy, A. E.; Pierson, E.; Hung, D. T. Targeting Virulence: A New Paradigm for 
Antimicrobial Therapy. Nat. Chem. Biol. 2007, 3 (9), 541–548.  
(14)  Federle, M. J.; Bassler, B. L. Interspecies Communication in Bacteria. J. Clin. Invest. 2003, 112 
(9), 1291–1299.  
(15)  Herzberg, M.; Kaye, I. K.; Peti, W.; Wood, T. K. YdgG (TqsA) Controls Biofilm Formation in 
Escherichia Coli K-12 through Autoinducer 2 Transport. J. Bacteriol. 2006, 188 (2), 587–598.  
(16)  Rettner, R. E.; Saier, M. H. The Autoinducer-2 Exporter Superfamily. J. Mol. Microbiol. 
Biotechnol. 2010, 18 (4), 195–205. 
(17)  Globisch, D.; Lowery, C. A.; McCague, K. C.; Janda, K. D. Uncharacterized 4,5-Dihydroxy-2,3-
Pentanedione (DPD) Molecules Revealed Through NMR Spectroscopy: Implications for a 
Greater Signaling Diversity in Bacterial Species. Angew. Chem. Int. Ed. 2012, 51 (17), 4204–
4208.  
(18)  Chen, X.; Schauder, S.; Potier, N.; Van Dorsselaer, A.; Pelczer, I.; Bassler, B. L.; Hughson, F. 
M. Structural Identification of a Bacterial Quorum-Sensing Signal Containing Boron. Nature 
2002, 415 (6871), 545–549.  
(19)  Miller, S. T.; Xavier, K. B.; Campagna, S. R.; Taga, M. E.; Semmelhack, M. F.; Bassler, B. L.; 
Hughson, F. M. Salmonella Typhimurium Recognizes a Chemically Distinct Form of the 
Bacterial Quorum-Sensing Signal AI-2. Mol. Cell 2004, 15 (5), 677–687.  
(20)  Ha, J.-H.; Eo, Y.; Grishaev, A.; Guo, M.; Smith, J. A. I.; Sintim, H. O.; Kim, E.-H.; Cheong, H.-
K.; Bentley, W. E.; Ryu, K.-S. Crystal Structures of the LsrR Proteins Complexed with Phospho-
AI-2 and Two Signal-Interrupting Analogues Reveal Distinct Mechanisms for Ligand 
Recognition. J. Am. Chem. Soc. 2013, 135 (41), 15526–15535.  
(21)  Xavier, K. B.; Bassler, B. L. Regulation of Uptake and Processing of the Quorum-Sensing 
Autoinducer AI-2 in Escherichia Coli. J. Bacteriol. 2005, 187 (1), 238–248.  
(22)  Marques, J. C.; Lamosa, P.; Russell, C.; Ventura, R.; Maycock, C.; Semmelhack, M. F.; Miller, 
S. T.; Xavier, K. B. Processing the Interspecies Quorum-Sensing Signal Autoinducer-2 (AI-2): 
Characterization of Phospho-(S)-4,5-Dihydroxy-2,3-Pentanedione Isomerization by LsrG 
Protein. J. Biol. Chem. 2011, 286 (20), 18331–18343.  
(23)  Penesyan, A.; Gillings, M.; Paulsen, I. T. Antibiotic Discovery: Combatting Bacterial Resistance 
in Cells and in Biofilm Communities. Mol. Basel Switz. 2015, 20 (4), 5286–5298.  
(24)  Kociolek, M. Quorum-Sensing Inhibitors and Biofilms. Anti-Infect. Agents Med. Chem. 2009, 8 
(4), 315–326.  
(25)  Brackman, G.; Coenye, T. Quorum Sensing Inhibitors as Anti-Biofilm Agents. Curr. Pharm. 
Des. 2015, 21 (1), 5–11. 
(26)  Mandabi, A.; Ganin, H.; Meijler, M. M. Synergistic Activation of Quorum Sensing in Vibrio 
Harveyi. Bioorg. Med. Chem. Lett. 2015, 25 (18), 3966–3969.  
(27)  Lowery, C. A.; Park, J.; Kaufmann, G. F.; Janda, K. D. An Unexpected Switch in the 
Modulation of AI-2-Based Quorum Sensing Discovered through Synthetic 4,5-Dihydroxy-2,3-
Pentanedione Analogues. J. Am. Chem. Soc. 2008, 130 (29), 9200–9201.  
(28)  Ganin, H.; Tang, X.; Meijler, M. M. Inhibition of Pseudomonas Aeruginosa Quorum Sensing by 
AI-2 Analogs. Bioorg. Med. Chem. Lett. 2009, 19 (14), 3941–3944.  
(29)  Smith, J. A. I.; Wang, J.; Nguyen-Mau, S.-M.; Lee, V.; Sintim, H. O. Biological Screening of a 
Diverse Set of AI-2 Analogues in Vibrio Harveyi Suggests That Receptors Which Are Involved 
in Synergistic Agonism of AI-2 and Analogues Are Promiscuous. Chem. Commun. 2009, No. 
45, 7033. 
(30)  Roy, V.; Smith, J. A. I.; Wang, J.; Stewart, J. E.; Bentley, W. E.; Sintim, H. O. Synthetic 
Analogs Tailor Native AI-2 Signaling across Bacterial Species. J. Am. Chem. Soc. 2010, 132 
(32), 11141–11150.  
(31)  Gamby, S.; Roy, V.; Guo, M.; Smith, J. A. I.; Wang, J.; Stewart, J. E.; Wang, X.; Bentley, W. E.; 
Sintim, H. O. Altering the Communication Networks of Multispecies Microbial Systems Using a 
Diverse Toolbox of AI-2 Analogues. ACS Chem. Biol. 2012, 7 (6), 1023–1030.  
(32)  Frezza, M.; Balestrino, D.; Soulère, L.; Reverchon, S.; Queneau, Y.; Forestier, C.; Doutheau, A. 
Synthesis and Biological Evaluation of the Trifluoromethyl Analog of (4S)-4,5-Dihydroxy-2,3-
Pentanedione (DPD). Eur. J. Org. Chem. 2006, 2006 (20), 4731–4736.  
(33)  Kadirvel, M.; Fanimarvasti, F.; Forbes, S.; McBain, A.; Gardiner, J. M.; Brown, G. D.; Freeman, 
S. Inhibition of Quorum Sensing and Biofilm Formation in Vibrio Harveyi by 4-Fluoro-DPD; a 
Novel Potent Inhibitor of Signalling. Chem. Commun. Camb. Engl. 2014, 50 (39), 5000–5002.  
(34)  Zhang, Y.; Zagnitko, O.; Rodionova, I.; Osterman, A.; Godzik, A. The FGGY Carbohydrate 
Kinase Family: Insights into the Evolution of Functional Specificities. PLoS Comput Biol 2011, 
7 (12), e1002318.  
(35)  Tsuchikama, K.; Zhu, J.; Lowery, C. A.; Kaufmann, G. F.; Janda, K. D. C4-Alkoxy-HPD: A 
Potent Class of Synthetic Modulators Surpassing Nature in AI-2 Quorum Sensing. J. Am. Chem. 
Soc. 2012, 134 (33), 13562–13564. 
(36)  Selvam, T. P.; James, C. R.; Dniandev, P. V.; Valzita, S. K. A Mini Review of Pyrimidine and 
Fused Pyrimidine Marketed Drugs. Res. Pharm. 2012, 2 (4), 1 – 9. 
(37)  Yerragunta, V.; Patil, P.; Anusha, V.; KumaraSwamy, T.; Suman, D.; Samhitha, T. Pyrimidine 
and Its Biological Activity: A Review. PharmaTutor 2013, 1 (2), 39–44. 
(38)  Kartsev, V. G. Natural Compounds In Drug Discovery. Biological Activity and New Trends in 
the Chemistry of Isoquinoline Alkaloids. Med. Chem. Res. 2004, 13 (6–7), 325–336.  
(39)  Galán, A.; Moreno, L.; Párraga, J.; Serrano, Á.; Sanz, M. J.; Cortes, D.; Cabedo, N. Novel 
Isoquinoline Derivatives as Antimicrobial Agents. Bioorg. Med. Chem. 2013, 21 (11), 3221–
3230.  
(40)  Iranshahy, M.; Quinn, R. J.; Iranshahi, M. Biologically Active Isoquinoline Alkaloids with 
Drug-like Properties from the Genus Corydalis. RSC Adv. 2014, 4 (31), 15900–15913.  
(41)  Chlebek, J.; Novák, Z.; Kassemová, D.; Šafratová, M.; Kostelník, J.; Malý, L.; Ločárek, M.; 
Opletal, L.; Hošt’álková, A.; Hrabinová, M.; Kuneš, J.; Novotná, P.; Urbanová, M.; Nováková, 
L.; Macáková, K.; Hulcová, D.; Solich, P.; Pérez Martín, C.; Jun, D.; Cahlíková, L. Isoquinoline 
Alkaloids from Fumaria Officinalis L. and Their Biological Activities Related to Alzheimer’s 
Disease. Chem. Biodivers. 2016, 13 (1), 91–99.  
(42)  Marty, M.; Fumoleau, P.; Adenis, A.; Rousseau, Y.; Merrouche, Y.; Robinet, G.; Senac, J.; 
Puozzo, C. Oral Vinorelbine Pharmacokinetics and Absolute Bioavailability Study in Patients 
with Solid Tumors. Ann. Oncol. 2001, 12 (11), 1643–1649.  
(43)  Faller, B. A.; Pandit, T. N. Safety and Efficacy of Vinorelbine in the Treatment of Non-Small 
Cell Lung Cancer. Clin. Med. Insights Oncol. 2011, 5, CMO.S5074.  
(44)  Chadha, N.; Silakari, O. Indoles as Therapeutics of Interest in Medicinal Chemistry: Bird’s Eye 
View. Eur. J. Med. Chem. 2017, 134, 159–184. https://doi.org/10.1016/j.ejmech.2017.04.003. 
(45)  Altaf, A. A.; Shahzad, A.; Gul, Z.; Rasool, N.; Badshah, A.; Lal, B.; Khan, E. A Review on the 
Medicinal Importance of Pyridine Derivatives. J. Drug Des. Med. Chem. 2015, 1 (1), 1.  
(46)  Lucas, S. The Pharmacology of Indomethacin. Headache J. Head Face Pain 2016, 56 (2), 436–
446.  
(47)  Naim, M. J.; Alam, O.; Nawaz, F.; Alam, M. J.; Alam, P. Current Status of Pyrazole and Its 
Biological Activities. J. Pharm. Bioallied Sci. 2016, 8 (1), 2–17. https://doi.org/10.4103/0975-
7406.171694. 
(48)  Faria, J. V.; Vegi, P. F.; Miguita, A. G. C.; dos Santos, M. S.; Boechat, N.; Bernardino, A. M. R. 
Recently Reported Biological Activities of Pyrazole Compounds. Bioorg. Med. Chem. 2017, 25 
(21), 5891–5903.  
(49)  Stotani, S.; Gatta, V.; Medda, F.; Padmanaban, M.; Karawajczyk, A.; Tammela, P.; Giordanetto, 
F.; Tzalis, D.; Collina, S. A Versatile Strategy for the Synthesis of 4,5-Dihydroxy-2,3-
Pentanedione (DPD) and Related Compounds as Potential Modulators of Bacterial Quorum 
Sensing. Molecules 2018, 23 (10), 2545.  
(50)  Karpov, A. S.; Müller, T. J. J. Straightforward Novel One-Pot Enaminone and Pyrimidine 
Syntheses by Coupling-Addition-Cyclocondensation Sequences. Synthesis 2003, 2003 (18), 
2815–2826. 
(51)  Palimkar, S. S.; Kumar, P. H.; Jogdand, N. R.; Daniel, T.; Lahoti, R. J.; Srinivasan, K. V. 
Copper-, Ligand- and Solvent-Free Synthesis of Ynones by Coupling Acid Chlorides with 
Terminal Alkynes. Tetrahedron Lett. 2006, 47 (31), 5527–5530.  
(52)  Cox, R. J.; Ritson, D. J.; Dane, T. A.; Berge, J.; Charmant, J. P. H.; Kantacha, A. Room 
Temperature Palladium Catalysed Coupling of Acyl Chlorides with Terminal Alkynes. Chem. 
Commun. 2005, 8, 1037–1039.  
(53)  Xiong, X.; Bagley, M. C.; Chapaneri, K. A New Mild Method for the One-Pot Synthesis of 
Pyridines. Tetrahedron Lett. 2004, 45 (32), 6121–6124.  
(54)  Medarametla, P.; Gatta, V.; Kajander, T.; Laitinen, T.; Tammela, P.; Poso, A. Cover Feature: 
Structure-Based Virtual Screening of LsrK Kinase Inhibitors to Target Quorum Sensing. 
ChemMedChem 2018, 13 (22), 2350–2350.  
(55)  Walsh, F. Superbugs to Kill “More than Cancer.” BBC News. December 11, 2014. 
(56)  Yang, D.; Burugupalli, S.; Daniel, D.; Chen, Y. Microwave-Assisted One-Pot Synthesis of 
Isoquinolines, Furopyridines, and Thienopyridines by Palladium-Catalyzed Sequential 
Coupling–Imination–Annulation of 2-Bromoarylaldehydes with Terminal Acetylenes and 
Ammonium Acetate. J. Org. Chem. 2012, 77 (9), 4466–4472.  
(57)  Karpov, A. S.; Müller, T. J. J. Straightforward Novel One-Pot Enaminone and Pyrimidine 
Syntheses by Coupling-Addition-Cyclocondensation Sequences. Synthesis 2003, 2003 (18), 
2815–2826.  
(58)  Trost, B. M.; Hung, C.-I. (Joey). Broad Spectrum Enolate Equivalent for Catalytic Chemo-, 
Diastereo-, and Enantioselective Addition to N-Boc Imines. J. Am. Chem. Soc. 2015, 137 (50), 
15940–15946.  
(59)  Xavier, K. B.; Miller, S. T.; Lu, W.; Kim, J. H.; Rabinowitz, J.; Pelczer, I.; Semmelhack, M. F.; 
Bassler, B. L. Phosphorylation and Processing of the Quorum-Sensing Molecule Autoinducer-2 
in Enteric Bacteria. ACS Chem. Biol. 2007, 2 (2), 128–136.  
(60)  Small-Molecule Drug Discovery Suite | Schrödinger. https://www.schrodinger.com/suites/small-
molecule-drug-discovery-suite  
  
Table of Content graphic 
 
